

MOLECULAR MECHANISMS REGULATING MYOGENIC DETERMINATION AND DIFFERENTIATION

Robert L.S. Perry¹ and Michael A. Rudnicki^{1,2}

¹ Department of Biology, McMaster University, Hamilton, Ontario, Canada L8S 4K1. ² Institute for Molecular Biology and Biotechnology (MOBIX), McMaster University, Hamilton, Ontario, Canada, L8S 4K1

TABLE OF CONTENTS

1. Abstract
2. Introduction
3. Development and determination of the myogenic lineage
 - 3.1. Somitogenesis: formation of epaxial versus hypaxial musculature
 - 3.2. The myogenic regulatory factors
 - 3.2.1. Developmental expression of the myogenic regulatory factors
 - 3.2.2. Lessons from gene targeting
 - 3.3. Regulation of myogenesis during development
 - 3.3.1. Extracellular cues and myogenic determination
 - 3.3.2. Genes important for myoblast migration during development
 - 3.4. Regulation of terminal differentiation
 - 3.4.1. Cell cycle and myogenesis
 - 3.4.2. The MEF2 family of transcription factors
 - 3.4.3. Growth factors and signal transduction
 - 3.4.4. Functional protein-protein interactions
 - 3.5. Regeneration of adult skeletal muscle
 - 3.5.1. Satellite cells
 - 3.5.2. Satellite cell origin
 - 3.5.3. Stem-cells in skeletal muscle
4. Perspectives
5. Acknowledgements
6. References

1. ABSTRACT

The myogenic regulatory factors are necessary for the determination and terminal differentiation of skeletal muscle. Gene targeting experiments have demonstrated that MyoD and Myf5 are important for myogenic determination whereas myogenin and MRF4 are important for terminal differentiation and lineage maintenance. During development, all trunk skeletal muscle is derived from the somite. Two spatially distinct sources of myogenic progenitors are defined by the expression of *MyoD* or *Myf5* and these give rise to hypaxial and epaxial musculature. Both *in vivo* and *in vitro* analyses have provided a detailed picture regarding the molecular events controlling lineage determination, cell migration, terminal differentiation and tissue repair. Signal transduction pathways regulating cell cycle, protein-protein interactions and myogenic factor gene activation are implicated in the regulation of myogenesis. Recent experiments examining the origin and stem-cell capacity of satellite cells suggest that these cells may originate from the vascular system, are multipotential and may be useful for the treatment of several degenerative diseases.

2. INTRODUCTION

Skeletal muscle represents an ideal model system for the study of many biological problems. Distinct molecular markers exist that permit detailed analyses of myogenic determination, myoblast proliferation and terminal differentiation. The myogenic regulatory factors are vital to the determination and maintenance of skeletal muscle. During development, the induction of *MyoD* and *Myf5* expression defines the origin of myogenic progenitor cells (mpcs) that are responsible for forming distinct muscle groups of the adult organism. Gene targeting and transgenic mice have provided insight into the genetic relationships within the myogenic regulatory factor family and with molecules expressed within presumptive myogenic lineages. Interesting new insights have been uncovered explaining the molecular mechanisms that govern both proliferation and terminal differentiation. A number of signaling pathways have been shown to regulate myogenesis during development and regeneration of damaged tissue in the adult. These pathways regulate cell cycle progression, protein-protein interactions and transcriptional activity of the myogenic factors.




Figure 1: Somitic origin of the trunk musculature. The left side depicts events that occur in somites at the thoracic level and the right side shows events at limb-level somites. Dermomyotomal expansion leads to the extension of cells from the dorsomedial lip (DML) to a position beneath the dermomyotome. This marks the formation of the epaxial myotome which can be identified by *Myf5* expression. A similar extension occurs at the ventrolateral lip (VLL) forming the hypaxial myotome. The cells of the hypaxial myotome predominantly express *MyoD*. At the limb level, cells in the VLL delaminate and migrate to the developing limbs. These cells are *Pax3*, *Lbx1*, *c-Met* and *Msx1* positive. Upon arrival, these cells down-regulate *Pax3* and initiate expression of the myogenic regulatory factors, in particular *MyoD*. Formation of the body wall musculature occurs via a continued ventral expansion of the myotome. It should be noted that the first appearance of the epaxial myotome occurs at day 8.5 whereas the first appearance of the hypaxial myotome is at day 9.5. NT=neural tube; NC=notocord.

Furthermore, the use of the *mdx* mouse, which represents a model system for Duchenne's muscular dystrophy, is expanding our knowledge of skeletal muscle diseases and uncovering novel insights regarding satellite cell origins and potential therapies to alleviate the debilitating effects of these diseases.

In this review, we will provide the reader with a basic understanding of the molecular events that are responsible for regulating myogenic commitment, myoblast proliferation and terminal differentiation. Furthermore, we briefly outline exciting new developments in myogenic stem cell research.

3. DETERMINATION AND DEVELOPMENT OF THE MYOGENIC LINEAGE

3.1. Somitogenesis: formation of epaxial versus hypaxial musculature

The formation of somite pairs on either side of the neural tube marks a crucial event during vertebrate development (for review see 1). Somites form in a rostral

to caudal direction and epithelization begins about day 7.5 postcoitum (p.c.) in the mouse. As development proceeds, somites become subdivided into the ventral sclerotome and dorsal dermomyotomal domains. Sclerotomal cells give rise to the vertebrae and the ribs whereas the dermomyotome gives rise to the dermis of the back and the adult skeletal musculature of the trunk (reviewed in 2 and 3). Early experimentation using quail-chick somite grafts demonstrated that medial and lateral portions of somite are patterned by secreted factors from surrounding tissues and give rise to two distinct populations of myoblasts (4,5,6). Cells of the medial portion of the somite give rise to the muscles of the deep back, or epaxial muscles, whereas the lateral portion develops into the muscles of the body wall and limbs, or hypaxial muscles (5).

In birds, myotome formation occurs in sequential stages (for review see 7 and 8). First, cells in the dorsomedial lip (DML) extend beneath the dermomyotome, exit the cell cycle, elongate and terminally differentiate (9,10). These pioneer cells mark the first appearance of the

myotome and are followed shortly after formation by a second wave of cells migrating from the rostral and caudal portions of the somite (11). The cells of the second wave originate in the DML and are dependent upon migration to enter the myotome from the correct position (11,12). Myotomal development from cells originating in the DML represents the epaxial portion of the myotome. A similar series of events occurs at the ventral lateral lip (VLL) of the dermomyotome leading to the formation of the non-migratory hypaxial portion of the myotome (12,13). Subsequent expansion of the myotome occurs from the more superficial to deep regions of the myotome (12).

At the limb level, events at the VLL occur differently (Figure 1). Cells of the VLL undergo an epithelial to mesenchymal transition, delaminate from the dermomyotome and migrate to regions of presumptive muscle development in the limbs (for review see 14). Limb muscle formation occurs in temporally distinct waves involving at least two populations of cells that give rise to primary and secondary myotubes (6). *In vitro* characterization has shown that these two cell populations are distinguishable on the basis of clonal morphology and media requirements (15,16,17). Moreover, the myosin heavy chain isoforms expressed by early and late cells differ suggesting primary myoblasts are destined to give rise to slow muscle fibers whereas secondary myoblasts give rise to fast muscle fibers (for review see 18). *In vivo* analyses of somite and limb grafts suggest that these early and late populations do indeed give rise to slow and fast fibers, respectively (19). Although injection of embryonic myoblasts into limbs of developing birds suggested that their lineage is maintained (20,21), experiments in adults support a model in which environmental cues, such as innervation, play a substantial role in determining fiber-type potential (22,23).

A third wave of migration, which represents the adult satellite cells, can be detected during the midfetal gestational stage in birds (24). These cells appear to be of somitic origin (25), and are responsible for the majority of postnatal skeletal muscle growth (26,27). *In vitro*, these cells can be phenotypically distinguished from primary and secondary myoblast populations (28,29,30). Interestingly, analysis of clonal cultures from adult avian muscle suggests that satellite cells express a phenotype that is consistent with their fiber-type origin, although continued passaging of these cells indicates phenotypic plasticity (29). Taken together, development of vertebrate trunk musculature involves multiple cell lineages that arise from spatially distinct regions of the somite. The myogenic regulatory factors (MRFs) are critical for the appropriate determination, development and maintenance of these skeletal muscle lineages. We will now discuss the current knowledge regarding the MRFs and how their expression and activity during embryogenesis is regulated.

3.2. The myogenic regulatory factors

The original cloning of *MyoD* and demonstration that it represents a master regulatory gene for the determination of skeletal muscle, ushered in a new era of research in skeletal myogenesis (31). This discovery led to

the cloning of three other factors namely *Myf5* (32), *myogenin* (33,34), and *MRF4/Myf-6/Herculin* (35,36,37). In all cases, overexpression of these factors converts non-muscle cells to the myogenic lineage, demonstrating their role in myogenic lineage determination and differentiation. Furthermore, the ability of each factor to initiate the expression of one or more of the other three suggests they form a cross-regulatory loop (38).

The MRFs belong to the basic helix-loop-helix (bHLH) superfamily of transcription factors which includes c-myc. The HLH domain is responsible for the dimerization of these factors with the ubiquitously expressed E-proteins, such as E12, E47, HEB, and ITF, and the basic domain is responsible for DNA binding (39,40,41). Heterodimers bind to the consensus E-box (CANNTG) DNA sequence motif found in the promoters of many muscle specific genes (40,42,43). The bHLH domains of the MRFs are highly homologous while the amino and carboxyl terminals show limited homology. Structurally, the MRFs contain several functionally distinct domains responsible for transcriptional activation, chromatin remodeling, DNA binding, nuclear localization and heterodimerization (44,45,46,47,48).

3.2.1. Developmental expression of the myogenic regulatory factors

During development the MRFs are expressed in a highly regulated spatial and temporal fashion (reviewed in 49,50). *In situ* hybridization analyses demonstrate that MRF expression occurs in slightly different patterns in epaxial versus hypaxial muscle. *Myf5* expression is detected in the dorsomedial portion of the somite at day 8 p.c. and at day 9.5 in the lateral, or hypaxial domain of the somite (51,52). *Myogenin* is first detected at day 8.5 p.c. and remains detectable throughout fetal development (53). *MRF4* expression is detected transiently between days 10 and 11 and then reexpressed from day 16 onward to become the predominant MRF expressed in adult muscle (54,55,56). *MyoD* expression is first detected approximately day 9.75 in the hypaxial somitic domain and continues to be expressed throughout development (54,57). In the limb bud, the temporal appearance of these factors is slightly different. Although *Myf5* expression is again detected first, it is followed very quickly by *MyoD* and *myogenin* which are detected from day 10.5 onward (51,53). Unlike observations in the somite, *MRF4* is not transiently expressed during limb development but is first detected at day 16 and becomes the predominant MRF expressed in the adult (54,55). Analysis of protein expression has confirmed the *in situ* hybridization results with the dorsal and ventral subdomains of the myotome predominantly expressing *Myf5* and *MyoD*, respectively (50).

3.2.2. Lessons from gene targeting

Targeted inactivation of the MRFs has provided a great deal of insight into the nature of lineage determination, lineage maintenance and their genetic relationships. Mice lacking a functional copy of *MyoD* are viable without any obvious defects in skeletal muscle (58). In a similar fashion, targeted inactivation of the *Myf5* gene




Figure 2: Functional and genetic relationships of the MRFs. Gene targeting experiments indicate that Myf5 and MyoD are required for the determination of the myogenic lineage. By contrast, terminal differentiation is dependent upon myogenin and MRF4.

gives rise to mice with seemingly normal muscle although these mice die perinatally due to a severe rib development defect (59). *Myf5* null mice do not show changes in the expression pattern of the other MRFs but do demonstrate a delay in myotome development (59). Mice lacking both *MyoD* and *Myf5* genes show a complete absence of myoblasts and muscle fibers. This demonstrates that at least one of these factors is required for determining the myogenic lineage during embryonic development and activation of *myogenin* and *MRF4* are dependent upon the preceding expression of *MyoD* and/or *Myf5* (60).

Gene targeting of the *myogenin* locus provided the first indication of the importance of the MRFs during development. In accordance with the appearance of myogenin at the onset of differentiation, lack of myogenin leads to perinatal death due to a severe deficiency of differentiated muscle fibers in newborn mice (61,62). Areas of presumptive muscle development have normal numbers of myonuclei and these cells are capable of differentiation when cultured *in vitro* (62). Interestingly, closer examination of *myogenin* null mice indicates that primary muscle fiber formation is unaffected whereas there are defects in secondary fiber myogenesis (63).

Three laboratories inactivated the *MRF4* gene yielding a range of defective rib cage phenotypes (64,65,66). The severity of the rib phenotype correlates with perturbations in *Myf5* expression, which lies approximately 6 kilobases away suggesting cis-regulatory elements (67,68). The most severe rib defects are observed in mice that do not activate *Myf5* (64). Moderate perturbation of *Myf5* expression leads to alterations in myotomal muscle development and rib abnormalities (65). Mice with normal *Myf5* expression are born healthy and fertile with minor rib abnormalities and show a four-fold increase in *myogenin* expression (66,69). This suggests increases in myogenin levels are able to compensate for the lack of MRF4.

Together, the gene targeting experiments suggest a model (Figure 2) in which *MyoD* and *Myf5* act to determine the myoblast lineage whereas myogenin and MRF4 are important for differentiation and maintenance of the terminally differentiated state (70,71).

To further understand the functional relationships of the MRFs, mice lacking multiple MRFs or, mice in which the coding sequence of one MRF has been knocked-in to the locus of another, have been examined. Mice lacking functional copies of both *myogenin* and *MyoD*, *myogenin* and *Myf5*, *myogenin* and *MRF4* or lack all but *Myf5* are phenotypically identical to *myogenin* null mice indicating that myogenin is genetically downstream of both *MyoD* and *Myf5* (69,72,73). Surprisingly, mice lacking *MRF4* and *MyoD* yield a phenotype similar to that of myogenin null mice (72). This indicates that myogenin can only compensate for the lack of MRF4 in the presence of *MyoD* expression lending support to the hypothesis that different lineages are defined by *MyoD* and *Myf5* expression. Furthermore, the data suggests that *MyoD* and myogenin cooperate to define one lineage whereas *Myf5* and MRF4 define a distinct lineage.

Substitution of the coding region of myogenin into the *Myf5* locus (*Myf5^{myg-ki}*) rescues the rib defect in a *Myf5* null background (74). However, mice homozygous for *Myf5^{myg-ki}* in a *MyoD* null background die perinatally due to reduced muscle formation. Furthermore, *Myf5^{myg-ki}* in a *myogenin* null background are born with a *myogenin* null phenotype showing that the early expression of myogenin is unable to compensate at later time points of differentiation (75). It has been suggested that myogenic deficiencies observed in some multiple knock-out animals demonstrates that a critical threshold level of MRF expression is required to initiate terminal differentiation.

To obtain a greater understanding of how *MyoD* and *Myf5* serve to determine lineages within the developing myotome, our laboratory examined the expression patterns of two transgenes that drive the expression of the bacterial beta-galactosidase (*lacZ*) gene under control of *MyoD* promoter elements. The upstream MD6.0-*lacZ* (6.0 kilobases of upstream *MyoD* promoter sequence) is detected in differentiated myocytes (76), whereas the 258/-2.5*lacZ* transgene (which has the 258 base pair -20 kilobase core enhancer fused to 2.5 kilobases of the *MyoD* promoter) is detected in determined myoblasts (77).

Mice lacking *Myf5* demonstrate a 2.5 day delay in development of paraspinal, intercostal and limb muscles (78,79), confirming previous reports that delayed expression of *MyoD* in a *Myf5* null background marks the onset of muscle differentiation (80). By contrast, mice lacking *MyoD* demonstrate normal epaxial muscle formation while hypaxial muscle development is delayed approximately 2 days (78,79). These results provide strong evidence that epaxial musculature is dependent upon *Myf5* expression whereas *MyoD* is required for appropriate hypaxial muscle formation (81).




Figure 3: Extracellular growth factors which are important for myotomal development. Sonic hedgehog is secreted by both notochord and floor plate which serves to induce *Myf5* expression. Wnts, in particular *Wnt1*, secreted from the dorsal neural tube similarly induce *Myf5* expression in the epaxial myotome. By contrast, *Wnt7a* secreted from the dorsal ectoderm induces *MyoD* expression in the ventral myotome. *BMP4* secreted from the dorsal ectoderm and lateral plate mesoderm is important for repressing MRF activation and maintaining *Pax3* expression in cells of the dermomyotome and the migrating precursor population in the VLL. Both dorsal neural tube and the DML secrete noggin, inhibiting the repressive effects of *BMP4* on myogenesis. DML=dorsomedial lip; VLL=ventrolateral lip; DE=dorsal ectoderm; NT=neural tube; NC=notochord; MM=medial myotome; VM=ventral myotome.




Figure 4: Activation and self-renewal of satellite cells. Satellite cells are activated by trauma or weight bearing. Initially, cells express *MyoD* or *Myf5* and proliferate. Expression of both *MyoD* and *Myf5* is found in cells prior to differentiation and fusion onto the existing damaged fiber. Studies examining the role of *MyoD* during muscle regeneration suggest that *Myf5* expression may play a role in the self-renewal capacity of the satellite cell compartment since cells lacking *MyoD* do not exit the proliferative phase of activation and demonstrate a diminished capacity for differentiation. See text for details.

To examine whether the migratory hypaxial population of cells are affected in the absence of MRF expression, mice lacking both *MyoD* and *Myf5* were examined using the 258/-2.5*lacZ* transgene (82). Expression of *lacZ* is detected in both newly formed somites and limb buds. This pattern of staining demonstrates that in the absence of MRF expression activation of the -20 kilobase enhancer of *MyoD* occurs and cell migration to the limbs is unaffected (82). Interestingly, many *lacZ* positive cells in both the somitic and limb bud regions adopt non-myogenic fates suggesting these cells are multipotential (82). This confirms reports demonstrating that in the absence of *Myf5*, cells migrate abnormally and have an increased propensity to terminally differentiate along non-myogenic cell fates (83). The importance of *Myf5* for certain myogenic lineages is strengthened by the fact that smooth muscle cells of the esophagus are delayed in their transdifferentiation to skeletal muscle in the absence of *Myf5* expression (84).

Taken together, the data obtained from transgenic mice clearly demonstrates that *MyoD* and *Myf5* are responsible for the determination of two distinct populations of muscle cells in the myotome. However, the precise mechanisms involved with initiating the expression of *MyoD* versus *Myf5* remains unclear.

3.3. Regulation of myogenesis during development

3.3.1. Extracellular cues regulating myogenic determination

Several factors are expressed in axial and lateral regions of the developing embryo which are important for somite formation and the determination of cell lineages (Figure 3; for review see 85). Axial structures, such as the neural tube and notochord, provide signals necessary for epaxial myogenic determination (86-91). By contrast, the hypaxial myogenic lineage is dependent upon signals originating from the lateral plate mesoderm and dorsal ectoderm (92-97). Factors secreted from these structures include sonic hedgehog (*Shh*), Wnts, transforming growth factor- β (TGF- β)-like molecules, fibroblast growth factors (FGFs) and the bone morphogenic proteins (BMPs). All of these factors regulate myogenic determination and differentiation. However, there are differential effects observed between epaxial and hypaxial musculature.

Sonic hedgehog (*Shh*) is expressed in the notochord and neural floor plate and has been shown to positively regulate the formation and survival of the dorsal myotome (98-101). Mice lacking *Shh* show reduced *Myf5* expression in the epaxial myotome (102,103), however, formation of the hypaxial myotome and *MyoD* expression is unaffected (103). In association with *Shh*, several Wnts have been shown to induce myogenesis and are thought to synergistically act with *Shh* (99,104,105). Mice lacking both *Wnt-1* and *Wnt-3a* are unable to form the medial dermomyotome but show normal development of the lateral myotome (106). Interestingly, *Wnt-1* induces *Myf5* expression whereas *Wnt-7a*, which is expressed in the lateral plate mesoderm, induces *MyoD* expression (107). These results confirm previous studies demonstrating that the neural tube induces *Myf5* expression while the dorsal

Myogenic Determination and Differentiation

ectoderm preferentially activates *MyoD* expression (94). Taken together, this data indicates the importance of Shh and Wnt signaling during development. Moreover, it confirms the hypothesis that epaxial and hypaxial musculature represent distinct lineages dependent on *Myf5* and *MyoD* expression, respectively.

The BMPs belong to the TGF-beta family of secreted factors and information obtained thus far shows these factors negatively regulate myogenesis. In particular, BMP4 has been of some interest due to its high level of expression in the lateral plate mesoderm (93). Recent experiments looking at the effects of BMPs on cells strongly suggest BMP concentration gradients are vital for cells to respond appropriately (108). Low BMP levels in the limb bud maintain migrating, *Pax3* expressing myogenic precursor cells in a proliferative state and repress myogenesis. By contrast, high BMP concentrations induce cell death (108). Important aspects of BMP signaling are the patterns of expression of BMPs and their inhibitors follistatin, noggin and chordin. Expression of the BMP antagonist, noggin, in the DML and lateral plate regulates the development of both medial and lateral myogenic lineages (105,109,110). Indeed, ectopic expression of noggin in the lateral regions of the embryo represses *Pax3* expression, expands the *MyoD* expression domain, and induces myogenesis (110).

Several FGF and TGF-beta family members have been identified. Treatment of cultured myoblasts with these factors suggests they act to stimulate proliferation and repress terminal differentiation. However, *in vivo* these molecules are important for the formation and terminal differentiation of the dorsal myotome (111). Neutralizing antibodies to TGF-beta or basic-FGF (bFGF) inhibit myotomal induction by axial structures. Exposure of segmental plate explants to a combination of TGF-beta and bFGF induces myotome formation. TGF-beta acts to specify the cells to the myogenic lineages whereas bFGF acts to promote proliferation and cell survival (111). Other TGF-beta and FGF molecules have been shown to play a role during regeneration and these will be discussed below (Section 3.5.1).

Cell-cell contact during development represents an important mechanism that contributes to the formation of distinct cell types. The transmembrane proteins of the *Notch-Delta/Jagged* signaling pathway are involved with cell contact signaling (112). Upon interaction of a Notch expressing cell with a Delta/Jagged expressing cell, the intracellular portion of Notch is cleaved, translocates to the nucleus and suppresses differentiation. Overexpression of the cytoplasmic portion of Notch represses myogenesis (113). During development, *Notch2* is expressed in cells of the DML, which lie juxtaposed to *Delta* expressing cells in the developing somite (114,115). This suggests that Notch2 suppresses myogenic commitment prior to cells extending beneath the dermomyotome.

3.3.2. Genes important for myoblast migration during development

Migration of cells from the VLL to the developing limb buds is required for the formation of limb hypaxial musculature. The naturally occurring *spotch* mutant

mouse does not develop limb musculature (116). This is due to a loss-of-function mutation in the *Pax3* gene which is required for cells of the VLL to migrate (117-119). It should be noted that although migration of muscle precursor cells is impaired, transplantation of these cells from the VLL to the limb bud shows they are capable of terminal differentiation (120). Overexpression of *Pax3* in cells represses myogenesis suggesting that it is involved with maintaining migrating myoblasts in an undifferentiated state (108). Indeed, upregulation of *Pax3* occurs in cells exposed to BMP signals from the dorsal ectoderm and limb buds, thus permitting muscle precursor cells to migrate and proliferate prior to differentiation (93,108,121).

Although cells that do not migrate in *spotch* mice are specified to the myogenic lineage there is evidence that *Pax3* is involved with determination of the myogenic lineage. Generation of mice lacking *Myf5* in a *spotch* background demonstrates a surprising genetic relationship between *Pax3*, *MyoD* and *Myf5* (122,123). *Spotch* mice demonstrate normal myotomal development and activation of *MyoD*. However, *spotch* mice lacking *Myf5* do not form any musculature due to a lack of *MyoD* expression in the developing somite (122,123). Moreover, exposure of paraxial mesoderm explants to *Pax3* can induce myogenic differentiation, supporting a role for *Pax3* in activating *MyoD* in a *Myf5* independent pathway during somitogenesis (122).

The c-Met receptor tyrosine kinase and its cognate ligand hepatocyte growth factor/scatter factor (HGF/SF) are important for the migration of myogenic cells. Targeted disruption of the *c-Met* or *HGF/SF* genes leads to a similar phenotype as that observed in *spotch* mice (124,125). Similar to *spotch* mice, there are not any defects in myotomal development. Moreover, although migratory cells of the VLL do not delaminate and migrate to the limbs, they are specified to the myogenic lineage, as observed in *spotch* mice (124,126).

Lbx1 is a homeobox protein expressed in the VLL and in *Pax3* positive migrating cells. Targeted inactivation of *Lbx1* leads to a disruption of only a subset of forelimb muscles and complete ablation of hindlimb musculature (127-129). Specifically, forelimb extensor muscles are absent, implicating *Lbx1* in the dorsoventral migration pattern of myogenic precursor cells during development (127-129). Interestingly, *Lbx1* expression is not detected in the trunk-level dermomyotomes of *spotch* mice suggesting that in certain regions of the developing embryo, *Pax3* is involved with activation of *Lbx1* expression (130).

Msx1 is a homeodomain protein that demonstrates overlapping expression with *Pax3* and represses myogenesis *in vitro* (131). Interestingly, *Msx1* has recently been shown to be antagonistic to both *Pax3* and MRF expression. This regulation is mediated by direct interaction between *Msx1* and *Pax3*, blocking *Pax3* DNA binding, and is important for controlling the timing of myogenesis in the limb (132,133).

The molecules responsible for activating MRF expression during development are currently unknown. However, recent studies examining the expression and activity of Dach2, Eya, Six1 and Pax3 proteins have suggested one mechanism by which the MRFs may be activated in the myotome (134,135). These four molecules are expressed in the dermomyotome, myotome and the migratory population of cells in the VLL (135). Dach2 and Pax3 positively autoregulate the expression of each other and myogenesis is induced within the somite by expression of Dach2/Eya2 or Six1/Eya2 complexes (134). Although it is not known whether these transcription factor complexes activate the promoters of *MyoD* or *Myf-5* directly, it is clear that these proteins are likely responsible for the ability of ectopic Pax3 expression to induce myogenesis in non-muscle tissue (122).

3.4. Regulation of terminal differentiation

3.4.1. Cell cycle and myogenesis

Decreases in growth factor concentration represents a cue for myoblasts to exit the cell cycle and undergo terminal differentiation. As myoblasts exit the cell cycle, expression of cyclin/cdk (cyclin-dependent kinase) inhibitors and retinoblastoma protein (pRb) are upregulated (135-138). The importance of cyclin/cdk inhibitors and pRb has been demonstrated by the fact that overexpression of E1A, which renders pRb inactive, inhibits myogenesis and can permit terminally differentiated myotube nuclei to reenter S-phase (139,140). Similarly, myoblasts that lack a functional copy of *Rb* re-initiate DNA synthesis upon growth factor stimulation. However, unlike E1A mediated inactivation of pRb, *Rb* null cells are capable of differentiating in the absence of pRb suggesting that p130 and p107 can compensate during differentiation but, are unable to maintain the differentiated phenotype (141,142). Moreover, both MRF and MEF2 proteins are dependent on pRb expression for full gene activation (143,144).

Overexpression of cyclin D1, which is important for the G1-S transition, and increases in cyclin/cdk kinase activity inhibit myogenesis, possibly due to phosphorylation and destabilization of MyoD (145-147). The putative phosphorylation residue is serine-200 which, when mutated to alanine, leads to an increase in MyoD stability and activity (148). Furthermore, MyoD and Myf5 protein level oscillations during the cell cycle correlate with changes in cyclin expression and cyclin/cdk activity (149). Physiologically, cyclin D1 levels increase upon stimulation of myoblasts with tumor necrosis factor alpha (TNF-alpha), leading to inhibition of terminal differentiation (150).

During terminal differentiation, upregulation of cdk inhibitors is important for cell cycle withdrawal (151), resistance to apoptosis (152), MyoD stability (153) and for the induction of myogenin, which is necessary for the differentiation program to proceed (154). Recent data demonstrates a direct link between MyoD and cell cycle regulation (155,156). In proliferating myoblasts nuclear cdk4 binds MyoD and inhibits MyoD-mediated gene expression (155). Conversely, a short carboxyl-terminal sequence of MyoD can inhibit cyclin/cdk4-dependent phosphorylation of pRb, promoting terminal differentiation

(156). Furthermore, upregulation of the cyclin/cdk inhibitor p57^{KIP2} stabilizes MyoD by blocking cyclinE-cdk2 activity (153) and by direct interaction with MyoD (157). It is clear that a fine balance exists between cell cycle regulation and terminal differentiation.

3.3.2. The Mef2 family of transcription factors

Along with the MRFs, it has been suggested that the myocyte enhancer factor 2 (MEF2) family of transcription factors play a role in myogenesis (for review see 158,159). MEF2 proteins are members of the MADS (MCM1, agamous, deficiens, serum response factor) box-containing family of transcription factors. The MEF2 family consists of four members, MEF2A-D, and they demonstrate a widely distributed pattern of expression. Although much of the information regarding these factors demonstrates their importance in cardiac muscle, they have been shown to form autoregulatory loops with the MRFs and are important for the expression of many muscle-specific genes. Structurally, MEF2 proteins are composed of amino terminal MEF and MADS domains which are responsible for dimerization and DNA binding. The carboxyl terminal domains thought to be important for gene activation and kinase responsiveness (Black and Olson, 1998). Homo- and heterodimers bind an A/T rich DNA sequence element (C/TTA(A/T)₄TAG/A) which is found in the promoters of many muscle-specific genes (158).

Several lines of evidence suggest that MEF2 and MRFs synergistically activate gene expression. It is important to note that MEF2 expression is initiated after the onset of differentiation suggesting these factors are involved during later stages of terminal differentiation (159). At the level of gene expression, full activation of both *MRF4* and *myogenin* promoters require both MRF and MEF2 proteins (160,161). *In vitro*, MRF and MEF2 proteins are capable of interacting to activate gene expression by both indirect and direct mechanisms (162,163). In flies, ablation of the single *MEF2* gene results in an inability of muscle cells to differentiate (164). By contrast, targeted inactivation of the *MEF2C* gene in mice is embryonic lethal due to severe defects in cardiac morphogenesis (165). However, no defects in skeletal muscle were noted, possibly due to functional redundancy of the factors. Transgenic mice carrying a *lacZ* reporter gene regulated by MEF2 factors show that MEF2 activity is high during embryonic development but is not detected after birth (166). Downregulation of MEF2 activity suggests that MEF factors are regulated at a posttranslational level that is currently unknown (166).

3.4.2. Growth factors and signal transduction

The determination, maintenance and activation of the myogenic program during development is regulated by factors such as Shh, BMPs, FGFs and Wnts. To gain an understanding of how extracellular signals regulate myogenesis, several studies have been carried out using myoblast cell lines *in vitro*. Treatment of cells with growth factors and cytokines leads to the activation of several intracellular kinase pathways which ultimately lead to changes in gene expression, cell survival and cellular morphology (for review see 167). Many distinct

Myogenic Determination and Differentiation

mechanisms have been elucidated to explain how growth factors are able to repress or stimulate the myogenic program.

Protein kinase C (PKC) activity is increased in response to mitogenic stimulation. Overexpression of activated PKC represses MRF-mediated transcription of muscle-specific reporter vectors and terminal differentiation. Transcriptional activation and DNA-binding are regulated by the direct phosphorylation of a threonine residue in the basic domain of myogenin (168). Although this threonine residue is conserved in all four MRFs, PKC phosphorylation is specific for myogenin suggesting that PKC-mediated regulation of myogenesis involves other pathways (169).

Binding of ligands to cell-surface receptors initiates a cascade of events which leading to the activation of p21^{ras}. Overexpression activated p21^{ras} in 10T1/2 mouse fibroblasts inhibits MRF-mediated differentiation without altering DNA-binding or the inherent transcriptional activation properties of the MRFs (170). Interestingly, inhibition of MEK and rac/rho kinase pathways, which are activated by ras, do not rescue myogenesis suggesting these pathways are not involved in regulating terminal differentiation (171). However, more recent studies demonstrate that inhibition of the MEK signaling pathway alleviates the repressive effects of FGF on myoblast differentiation (172). Furthermore, overexpression of the MAPK phosphatase, MKP-1, which is normally upregulated during differentiation, is important for inhibiting MAPK activity and permitting differentiation (173). It should be noted that later stages of differentiation require MKP-1 downregulation for myoblast fusion and myotube formation (173). Taken together, it is clear that increases in MAPK signaling are required for transmitting growth signals and decreases in MAPK activity is required for myogenesis to proceed.

Insulin-like growth factors (IGFs) are known to positively regulate myogenesis. IGF stimulation leads to an increase in phosphatidylinositol 3-kinase (PI3'K) activity. Dominant negative forms of PI3'K or, inhibition of PI3'K activity using synthetic inhibitors, are able to block IGF-mediated differentiation (174-176). When IGF signaling is blocked, cells maintain high levels of Id proteins and are unable to upregulate p21^{Cip1} for cell cycle withdrawal (174). Conversely, expression of activated PI3'K is able to induce differentiation suggesting a direct role for PI3'K in myogenesis (176).

The lipid products resulting from stimulation of PI3'K activity serve to activate protein kinase B (PKB/Akt). During differentiation, PKB expression is upregulated and its activity is important for myocyte survival (177). Expression of a dominant negative form of PKB inhibits PI3'K and IGF stimulation of myogenesis indicating PKB lies downstream of these signals (178). Surprisingly, activated PKB is able to phosphorylate Raf, rendering the Raf/MEK/MAPK pathway inactive (179). Although this inhibition is important during differentiation, overexpression of activated PKB is unable to force differentiation under growth conditions suggesting the

involvement of mediators that are specifically expressed at the onset of myogenic differentiation (180).

In many cell lines, the absence of extracellular growth factor stimulation leads to apoptosis indicating that pathways exist that are essential for cell survival. Although platelet-derived growth factor (PDGF) and IGF elicit opposite responses in myoblast cell lines, either factor on its own is sufficient to prevent apoptosis (181). Two distinct pathways are utilized indicating that cell survival can be mediated by separate mechanisms (181). What is surprising is that myoblasts stimulated with PDGF, which is mitogenic, produce a transient PKB activation and prolonged ERK activation. By contrast, IGF leads to transient ERK activation and prolonged PKB activity suggesting that the decision to proliferate is dependent upon the length of time that the MAPK pathway is active (181). This mechanism has been proposed for regulating proliferation versus differentiation decisions in the pheochromocytoma cell line, PC12, although prolonged ERK activity leads to differentiation (182). It remains to be seen what molecular events occur in myoblasts to elicit these distinct responses to extracellular cues.

MEF2 proteins are positively regulated by both p38 stress-activated and MKK5/BMK1 kinase pathways (183-186). The finding that MEF2 factors represent downstream targets of these pathways suggests that activation of MEF2 transcriptional activity is an important step during myogenesis. Indeed, overexpression of p38 isoforms or, upstream activators, stimulates myogenesis (187,188). It is interesting to note that the gamma isoform of p38 (SAPK3-beta/ERK6) is highly expressed in skeletal muscle. Although expression of this kinase is upregulated upon differentiation, it does not appear to phosphorylate MEF2 proteins and therefore, its function remains unclear (187,189).

Slow and fast muscle fibers differ in their metabolic properties and the panel of contractile proteins that they express. Since intracellular levels of calcium are regulated by contraction speeds, it has been hypothesized that calcium activated signal transduction pathways are important for fiber-type specification (159). Calcineurin, which is a calcium-activated protein phosphatase, activates the NFAT (nuclear factor of activated T-cells) transcription factors by dephosphorylation. This permits nuclear translocation of NFATs where they interact with other transcription factors and activate gene expression (190). Interestingly, treatment of animals with cyclosporin A, an inhibitor of calcineurin, or overexpression of calcineurin in muscle causes a shift from fast to slow fibers (191-193). One potential mechanism by which NFATs are thought to alter fiber-type specific gene expression is by interaction with MEF2. Response of T-cells to changes in intracellular calcium levels is mediated by MEF2 proteins (194,195,196) and many fiber-type specific gene promoters contain both MEF2 and NFAT binding sites (159).

3.4.4. Functional protein-protein interactions

Growth factor stimulation increases AP-1 (fos/jun)-dependent gene expression. Expression of the *c-fos* gene is mediated by binding of the serum-response-

factor (SRF) to a serum-response-element (SRE) in the *c-fos* promoter. During differentiation, *c-fos* gene expression is downregulated leading to decreases in AP-1-mediated gene activation. MRF-mediated repression of *c-fos* expression requires an E-box element that overlaps the SRE in the *c-fos* promoter (197). It is unclear whether MRF-mediated repression represents a competition for binding sites or, if direct interaction between MRFs and SRF is required (198). Moreover, the finding that jun can interact directly with MyoD and inhibit MRF-mediated gene expression suggests that AP-1 and MRFs form an autoregulatory loop to control myogenesis (199,200).

MRFs require dimerization with E-proteins in order to bind DNA and activate gene expression. One potential level of regulation involves the Id factors. Id molecules contain a helix-loop-helix motif but lack a basic DNA-binding domain (201 and references therein). Id levels increase upon stimulation of cells with growth factors and dimerization of Id proteins with MRFs or E-proteins prevents DNA binding and MRF-mediated gene expression. Expression of a MyoD-E47 fusion protein is resistant to Id regulation demonstrating the functional significance of Id proteins in regulating MRF-mediated gene expression and terminal differentiation (202). Alterations in E-protein availability has also been shown to occur by the MyoR bHLH factor (203). MyoR is expressed specifically in skeletal muscle and its expression is downregulated upon differentiation. Unlike Id/E-protein dimers, MyoR/E-protein dimers bind DNA and serve to repress gene expression (203).

Although the *Mos* protooncogene is generally regarded as an upstream activator of the MAPK signal transduction pathway, activation of the *Mos* protooncogene in muscle cells stimulates myogenesis (204). *Mos*-mediated myogenic stimulation occurs at two levels. First, activated *Mos* stimulates dimerization of MyoD and E12 and second, MyoD directly interacts with *Mos*, inhibiting downstream *Mos*-mediated activation of the MEK/MAPK pathway (205,206). These results suggest that alterations in the dimerization status of the MRFs are important levels of myogenic regulation. Indeed, interaction of MRF/E-protein dimers with muscle LIM protein dramatically increases MRF/E-protein gene activation and stimulates myogenic differentiation (207).

Several molecules have been shown to interact with MyoD. Of particular interest is the regulation of MyoD activity by p300/CBP and PCAF. These molecules are vital for gene activation by altering the acetylation status of histone cores in DNA (208). The transactivation domain of MyoD and the MADS domain of MEF2 proteins interact with p300, which initiates cell cycle arrest and differentiation (209,210). Interestingly, the histone acetyltransferase (HAT) activity of p300 is dispensable for MRF-mediated gene expression and only serves to attract PCAF to the promoters of muscle-specific genes (211). Significantly, MyoD transcriptional activation requires the acetylation of several lysine residues located just amino terminal of the basic DNA-binding domain by PCAF (212). In light of the fact that under growth conditions MyoD

interacts with N-CoR (213), this suggests a molecular switch during activation of the myogenic program. Under proliferating conditions, MyoD association with N-CoR serves to attract histone deacetylases (213). As differentiation proceeds, N-CoR levels decrease and p300/PCAF complexes initiate MyoD-mediated gene expression. Indeed, the fact that MyoD has two domains necessary for chromatin remodeling lends support to this type of regulation (47).

3.5. Regeneration of adult skeletal muscle

3.5.1. Satellite cells

In adult muscle, approximately 5% of the myonuclei present in muscle fibers represent satellite cells (214). Normally, these cells are mitotically quiescent but can be induced to proliferate due to stresses, such as physical trauma or weight-bearing (for review see 215,216). Activated satellite cells undergo multiple rounds of cell division, exit the cell cycle and fuse onto the existing damaged fibers (215). Several potential factors exist within the area of damage that may serve to activate satellite cells (216). Single-cell RT-PCR (reverse-transcription polymerase chain reaction) experiments show that quiescent satellite cells do not express detectable levels of MRFs, but do express the *Met* receptor and the muscle cell adhesion molecule *M-cadherin* (217). Upon activation, cells express either *MyoD* or *Myf5*, but eventually express both prior to progression through the differentiation program (217). What is unclear is how the satellite cell compartment is renewed.

Insight into satellite cell renewal has come from experiments examining the role of the MRFs during regeneration. Although *MyoD* null mice are born without apparent defects in skeletal muscle, when these mice are interbred with the *mdx* mouse or, adult muscle is subjected to damage, muscle regeneration is severely impaired even though several myogenic cells are detected in the damaged area (218). *In vitro* analysis of cells isolated from adult *MyoD* null mice demonstrate that these cells are unable to progress through the normal differentiation program and are mitotically active under conditions that initiate terminal differentiation in wild-type control cells (219,220). Although *MyoD*^{-/-} cells express high levels of *Myf5*, their ability to terminally differentiate is impaired (219). Taken together, these results indicate that cells lacking MyoD may represent an intermediate phenotype between quiescent satellite cell and determined myogenic progenitor cell (mpc) (219,221). Moreover, the expression of *Myf5* alone is insufficient for differentiation, suggesting that renewal of the satellite cell compartment may be a function of *Myf5* expression (219,221).

More recent evidence suggests that the winged helix transcription factor MNF (myocyte nuclear factor) is essential for the maintenance of satellite cells. *MNF* expression is detected in quiescent satellite cells (222). Two alternatively spliced isoforms can be detected with the beta isoform expressed in quiescent cells and the alpha isoform in activated mpcs (223,224). Interestingly, mice lacking a functional copy of *MNF* show severe deficiencies in skeletal muscle regeneration and are unable to properly coordinate the

Myogenic Determination and Differentiation

expression of cell cycle and myogenic determination genes (224). This suggests that MNF serves to properly activate genes responsible for determining mpcs and activating the myogenic program.

During regeneration, expansion of the mpc compartment is necessary for proper muscle repair to occur. FGF6 demonstrates a skeletal muscle-specific pattern of expression (225-227). Mice lacking *FGF6* are born healthy and fertile with no developmental abnormalities in skeletal muscle (228,229). However, these mice demonstrate a reduced capacity for regeneration after mechanical injury or when interbred with the *mdx* mouse (228). Although *FGF6* null mice have normal numbers of satellite cells, activation of the regeneration program yields fewer MyoD and myogenin positive cells and an increased deposition of collagen in sites of regeneration. This suggests that FGF6 normally represses differentiation and permits expansion of the satellite cell compartment during adult skeletal muscle regeneration (228).

By contrast, targeted inactivation of the TGF-beta family member, GDF8 or myostatin, results in mice with substantial increases in muscle mass (230). Both hyperplasia and hypertrophy are responsible for this increase in muscle mass. Unlike FGF6, GDF8 is a negative regulator of myoblast proliferation and differentiation and is involved with hypertrophic effects which is mediated by satellite cells (230).

Information from previous sections has demonstrated that members of the TGF-beta family are responsible for repressing the determination of myogenic cells whereas FGF family members stimulate proliferation of myogenic cells. Of interest are recent studies showing that both ski and sno oncoproteins are antagonistic to TGF-beta signaling (231,232). Overexpression of ski/sno proteins induces myogenesis and can mediate skeletal muscle fiber hypertrophy (233,234). This indicates that expression of ski and sno proteins may antagonize the negative effects of TGF-beta signaling on myogenic determination and the regeneration program.

3.5.2. Satellite cell origin

Early experiments using quail-chick chimeras suggested that satellite cells were somitically derived (25). These cells enter the limbs of mouse embryos at about day 17.5 p.c. (30,235,236). More recent analyses examining satellite cell origin suggest that this cell population may actually arise in the dorsal aorta of embryonic mice (236). Cultured cells isolated from the dorsal aorta coexpress skeletal muscle-specific and endothelial markers, similar to adult satellite cells. Moreover, these cells are able to contribute to regenerating muscle (236). Although *spotch* and *c-Met* null mice do not have cells migrate into the limb during development, cells isolated from the limbs of these embryos are myogenic, further supporting the notion that at least some satellite cells originate from the vascular system (236).

3.5.3. Stem-cells in skeletal muscle

To determine whether regenerating muscle recruits cells from non-satellite cell origin, genetically marked bone-marrow was transplanted into mice to assess the cellular contribution of bone-marrow to regenerating muscle (237,238). In both studies, it was shown that

transplanted marrow cells are detected in regenerated fibers indicating that bone-marrow-derived-stem-cells contribute to skeletal muscle regeneration (237,238). Similar results are obtained when highly purified hematopoietic stem cells are injected intravenously into *mdx* mice (239). However, in all three cases, grafted cells do not contribute to the satellite cell compartment indicating that they are only capable of terminal differentiation (216).

To determine if muscle tissue contains stem cells similar to those found in bone marrow, cells isolated from adult muscle were subjected to a specialized FACS (fluorescence-activated cell sorting) technique (239). This method permits the isolation of stem cells on the basis of Hoechst 33342 dye exclusion (240,241). Analyses from adult skeletal muscle indicates that a population of stem-cells exists and these cells express muscle-specific markers *in vitro* (239). What is surprising is that intravenous injection of these cells indicates that not only are they capable of participating in muscle regeneration but they also contribute to the satellite cell compartment (239). Moreover, these cells also repopulate bone-marrow of lethally irradiated mice and give rise to the three major blood lineages (242). Similar studies have revealed that pluripotent stem-cells can be isolated from numerous different tissues, including neural tissue (243,244). The ability to isolate multipotential stem cells from numerous tissues may provide the raw material necessary for stem cell therapies for the treatment of several degenerative diseases including muscular dystrophies.

4. PERSPECTIVES

It is clear that a great deal of information has been obtained regarding many aspects of skeletal muscle development. The myogenic regulatory factors represent an ideal paradigm for the study of cell lineages and the molecular events required for the establishment of a terminally differentiated tissue. However, several questions remain concerning aspects of determination, proliferation and terminal differentiation. In particular, the molecules responsible for the *de novo* activation of *MyoD* and *Myf5* are unknown. Similarly, regulation of MRF activity during proliferation and terminal differentiation are poorly understood due to a lack of myoblast specific genes that have been identified to date. Although several signal transduction pathways and protein-protein interactions regulating MRF expression and activity have been described, how these processes are integrated represents a major challenge in muscle research. Moreover, coordination of cell cycle and terminal differentiation is complex and we are only now beginning to understand the **many** factors involved.

The recent investigations into satellite cell origin and the demonstration that multipotential stem-cells are readily isolated from adult tissue have raised a multitude of questions. The potential use of muscle-derived stem-cells for the treatment of many degenerative diseases is truly exciting. Research focussed on understanding the molecular nature of these cells and their potential uses will provide a great deal of insight into myogenesis.

5. ACKNOWLEDGEMENTS

We would like to thank Dr. Atsushi Asakura and Maura Parker for critical comments on the manuscript. Research in the laboratory of M.A.R. is sponsored by the Medical Research Council of Canada, Muscular Dystrophy Association, the National Institutes of Health and the Human Frontiers Science Program. M.A.R. is a member of the Canadian Genetic Diseases Network and a Research Scientist of the Medical Research Council of Canada.

6. REFERENCES

1. Brand-Saberi B & B. Christ: Evolution and development of distinct cell lineages derived from somites. *Curr Topics Dev Biol* 48, 1-42 (2000)
2. Dale K & O. Pourquie: A clock-work somite. *BioEssays* 22, 72-83 (2000)
3. Dockter J.: Sclerotome induction and differentiation. *Curr Topics Dev Biol* 48, 77-127 (2000)
4. Aoyama H & K. Asamoto: Determination of somite cells: independence of cell differentiation and morphogenesis. *Development* 104, 15-28 (1988)
5. Ordahl C & N.M. LeDouarin: Two myogenic lineages within the developing somite. *Development* 114, 339-353 (1992)
6. Hauschka S.: The embryonic origin of muscle. In: *Myology*. Eds: Engel A, Franzini-Armstrong C, McGraw-Hill, NY. 1, 1-373 (1994)
7. Kalcheim C, Y. Cinnamon & N. Kahane: Myotome formation: a multistage process. *Cell Tissue Res* 296, 161-173 (1999)
8. Ordahl C, B.A. Williams & W. Denetclaw: Determination and morphogenesis in myogenic progenitor cells: an experimental embryological approach. *Curr Topics Dev Biol* 48, 319-367 (2000)
9. Denetclaw W, B. Christ & C.P. Ordahl: Location and growth of epaxial precursor cells. *Development* 124, 1601-1610 (1997)
10. Kahane N, Y. Cinnamon & C. Kalcheim: The origin and fate of pioneer myotomal cells in the avian embryo. *Mech Dev* 74, 59-73 (1998)
11. Kahane N, Y. Cinnamon & C. Kalcheim: The cellular mechanism by which the dermomyotome contributes to the second wave of myotome development. *Development* 125, 4259-4271 (1998)
12. Denetclaw W & C.P. Ordahl: The growth of the dermomyotome and formation of early myotome lineages in thoracolumbar somites of chicken embryos. *Development* 127, 893-905 (2000)
13. Cinnamon Y, N. Kahane & C. Kalcheim: Characterization of the early development of specific hypaxial muscles from the ventrolateral myotome. *Development* 126, 4305-4315 (1999)
14. Ordahl C & B.A. Williams: Knowing chops from chuck: roasting MyoD redundancy. *BioEssays* 20, 357-362 (1998)
15. White N, P.H. Bonner, D.R. Nelson & S.D. Hauschka: Muscle development in vitro. A new conditioned medium effect on colony differentiation. *Exp Cell Res* 67, 479-482 (1975)

16. Rutz R, C. Haney & S.D. Hauschka: Spatial analysis of limb bud myogenesis: a proximodistal gradient of muscle colony-forming cells in chick embryo leg buds. *Dev Biol* 90, 399-411 (1982)
17. Seed J & S.D. Hauschka: Temporal separation of the migration of distinct myogenic precursor populations into the developing chick wing bud. *Dev Biol* 106, 389-393 (1984)
18. Stockdale F.: Myogenic cell lineages. *Dev Biol* 154, 284-298 (1992)
19. Van Swearingen J. & C. Lance-Jones: Slow and fast muscle fibers are preferentially derived from myoblasts migrating into the chick limb bud at different developmental times. *Dev Biol* 170, 321-337 (1995)
20. DiMario J, S.E. Fernyak & F.E. Stockdale: Myoblasts transferred to the limbs of embryos are committed to specific fibre fates. *Nature* 362, 165-167 (1993)
21. DiMario J & F.E. Stockdale: Differences in the developmental fate of cultured and noncultured myoblasts when transplanted into embryonic limbs. *Exp Cell Res* 216, 431-442 (1995)
22. Hughes S & H.M. Blau: Muscle fiber pattern is independent of cell lineage in postnatal rodent development. *Cell* 68, 659-671 (1992)
23. Pin C & P.A. Merrifield: Developmental potential of rat L6 myoblasts in vivo following injection into regenerating muscles. *Dev Biol* 188, 147-166 (1997)
24. Feldman J & F.E. Stockdale: Temporal appearance of satellite cells during myogenesis. *Dev Biol* 153, 217-226 (1992)
25. Armand O, A.M. Boutineau, A. Mauger, M.P. Pautou & M. Kieny: Origin of satellite cells in avian skeletal muscles. *Arch Anat Microsc Morphol Exp* 72, 163-181 (1983)
26. Schultz E.: Satellite cell behavior during skeletal muscle growth and regeneration. *Med Sci Sports Exerc* 21, S181-186 (1989)
27. Schultz E.: Satellite cell proliferative compartments in growing skeletal muscles. *Dev Biol* 175, 84-94 (1996)
28. Matsuda R, E. Bandman, & R. Strohman: Regenerating adult chicken skeletal muscle and satellite cell cultures express embryonic patterns of myosin and tropomyosin isoforms. *Dev Biol* 100, 478-488 (1983)
29. Feldman J & F.E. Stockdale: Skeletal muscle satellite cell diversity: satellite cells form fibers of different types in cell culture. *Dev Biol* 143, 320-334 (1991)
30. Hartley R, E. Bandman & Z. Yablonka-Reuveni: Skeletal muscle satellite cells appear during late chicken embryogenesis. *Dev Biol* 153, 206-216 (1992)
31. Davis R, P. Cheng, A.B. Lassar & H. Weintraub: Expression of a single transfected cDNA converts fibroblasts to myoblasts. *Cell* 51, 987-1000 (1987)
32. Braun T, G. Buschhausin-Denker, E. Bober, E. Tannich & H.H. Arnold: A novel human muscle factor related to but distinct from MyoD1 induces myogenic conversion in 10T1/2 fibroblasts. *EMBO J* 8, 701-709 (1989)
33. Wright W, D.A. Sassoon & V.K. Lin: Myogenin, a factor regulating myogenesis, has a domain homologous to MyoD1. *Cell* 56, 607-617 (1989)
34. Edmondson D & E.N. Olson: A gene with homology to the myc similarity region of MyoD1 is expressed during

- myogenesis and is sufficient to activate the muscle differentiation program. *Genes Dev* 3, 628-640 (1989)
35. Rhodes S & S.F. Konieczny: Identification of MRF4: a new member of the muscle regulatory factor gene family. *Genes Dev* 3, 2050-2061 (1989)
36. Braun T, E. Bober, B. Winter, N. Rosenthal & H.H. Arnold: Myf-6, a new member of the human gene family of myogenic determination factors: evidence for a gene cluster on chromosome 12. *EMBO J* 9, 821-831 (1990)
37. Miner J & B. Wold: Herculin, a fourth member of the MyoD family of myogenic regulatory genes. *Proc Natl Acad Sci USA* 87, 1089-1093 (1990)
38. Braun T, E. Bober, B. Buschhausen-Denker, S. Kotz, K.H. Grzeschik & H.H. Arnold: Differential expression of myogenic determination genes in muscle cells: possible autoactivation by the Myf gene products. *EMBO J* 8, 3617-3625 (1989)
39. Murre C, P.S. McCaw, H. Vaessin, M. Caudy, L.Y. Jan, Y.N. Jan, C.V. Cabrera, J.N. Buskin, S.D. Hauschka, A.B. Lassar, H. Weintraub & D. Baltimore: Interactions between heterologous helix-loop-helix proteins generate complexes that bind specifically to a common DNA sequence. *Cell* 58, 537-544 (1989)
40. Lassar A, J.N. Buskin, D. Lockshon, R.L. Davis, S. Apone, S.D. Hauschka & H. Weintraub: MyoD is a sequence-specific DNA binding protein requiring a region of myc homology to bind to the muscle creatine kinase enhancer. *Cell* 58, 823-831 (1989)
41. Lassar A, R.L. Davis, W.E. Wright, T. Kadesch, C. Murre, A. Voronova, D. Baltimore & H. Weintraub: Functional activity of myogenic HLH proteins requires hetero-oligomerization with E12/E47-like proteins in vivo. *Cell* 66, 305-315 (1991)
42. Murre C, P. S. McCaw & D. Baltimore: A new binding and dimerization motif in immunoglobulin enhancer binding, daughterless, MyoD, and myc proteins. *Cell* 56, 777-7783 (1989)
43. Blackwell T & H. Weintraub: Differences and similarities in DNA-binding preferences of MyoD and E2A protein complexes revealed by binding site selection. *Science* 250, 1104-1110 (1990)
44. Tapscott S, R.L. Davis, M.J. Thayer, P.F. Cheng, H. Weintraub & A.B. Lassar: MyoD1: a nuclear phosphoprotein requiring a myc homology region to convert fibroblasts to myoblasts. *Science* 242, 405-411 (1988)
45. Weintraub H, V.J. Dwarki, I. Verma, R. Davis, S. Hollenberg, L. Snider, A. Lassar & S.J. Tapscott: Muscle-specific transcriptional activation by MyoD. *Genes Dev* 5, 1377-1386 (1991)
46. Vandomme M, J.C. Cavadore, A. Bonniieu, A. Froeschle, N. Lamb & A. Fernandez: Two nuclear localization signals present in the basic-helix 1 domains of MyoD promote its active nuclear translocation and can function independently. *Proc Natl Acad Sci USA* 92, 4646-4650 (1995)
47. Gerber A, T.R. Klesert, D.A. Bergstrom & S.J. Tapscott: Two domains of MyoD mediate transcriptional activation of genes in repressive chromatin: a mechanism for lineage determination in myogenesis. *Genes Dev* 11, 436-450 (1997)
48. Schwarz J, T. Chakraborty, J. Martin, J. Zhou & E.N. Olson: The basic region of myogenin cooperates with two transcription activation domains to induce muscle-specific transcription. *Mol Cell Biol* 12, 266-275 (1992)
49. Arnold H & T. Braun: Genetics of muscle determination and development. *Curr Topics Dev Biol* 48, 129-164 (2000)
50. Tajbakhsh S & M. Buckingham: The birth of muscle progenitor cells in the mouse: spatiotemporal considerations. *Curr Topics in Dev Biol* 48, 225-268 (2000)
51. Ott M, E. Bober, G. Lyons, H.H. Arnold & M. Buckingham: Early expression of the myogenic regulatory gene, Myf-5, in precursor cells of skeletal muscle in the mouse embryo. *Development* 111, 1097-1107 (1991)
52. Tajbakhsh S, E. Bober, C. Babinet, S. Pourin, H.H. Arnold & M. Buckingham: Gene targeting the myf-5 locus with nlacZ reveals expression of this myogenic factor in mature skeletal muscle fibers as well as early embryonic muscle. *Dev Dyn* 206, 291-300 (1996)
53. Sassoon D, G. Lyons, W.E. Wright, V. Lin, A. Lassar, H. Weintraub & M. Buckingham: Expression of two myogenic regulatory factors myogenin and MyoD1 during mouse embryogenesis. *Nature* 344, 303-307 (1989)
54. Bober E, G.E. Lyons, T. Braun, G. Cossu, M. Buckingham & H.H. Arnold: The muscle regulatory gene Myf-6 has a biphasic pattern of expression during early mouse development. *J Cell Biol* 113, 1255-1265 (1991)
55. Hinterberger T, D.A. Sassoon, S.J. Rhodes & S.F. Konieczny: Expression of the muscle regulatory factor MRF4 during somite and skeletal myofiber development. *Dev Biol* 147, 144-156 (1991)
56. Hannon K, C.K.D. Smith, K.R. Bales & R.F. Santerre: Temporal and quantitative analysis of myogenic regulatory and growth factor gene expression in the developing mouse embryo. *Dev Biol* 151, 137-144 (1992)
57. Faerman A, D.J. Goldhamer, R. Puzis, C.P. Emerson & M. Shani: The distal human MyoD enhancer sequences direct unique muscle-specific patterns of lacZ expression during mouse development. *Dev Biol* 171, 27-38 (1995)
58. Rudnicki M, T. Braun, S. Hinuma & R. Jaenisch: Inactivation of MyoD in mice leads to up-regulation of the myogenic HLH gene Myf-5 and results in apparently normal muscle development. *Cell* 71, 383-390 (1992)
59. Braun T, M.A. Rudnicki, H.H. Arnold & R. Jaenisch: Targeted inactivation of the muscle regulatory factor gene Myf-5 results in abnormal rib development and perinatal death. *Cell* 71, 369-382 (1992)
60. Rudnicki M, P.N.J. Schnegelsberg, R.H. Stead, T. Braun, H.H. Arnold & R. Jaenisch: MyoD or Myf-5 is required for the formation of skeletal muscle. *Cell* 75, 1351-1359 (1993)
61. Hasty P, A. Bradley, J.H. Morris, D.G. Edmondson, J.M. Venuiti, E.N. Olson & W.H. Klein: Muscle deficiency and neonatal death in mice with a targeted mutation in the myogenin gene. *Nature* 364, 501-532 (1993)
62. Nabeshima Y, K. Hanaoka, M. Hayasaka, E. Esumi, S. Li, I. Nonaka & Y. Nabeshima: Myogenin gene disruption results in perinatal lethality because of severe muscle defect. *Nature* 364, 532-535 (1993)
63. Venuiti J, J.H. Morris, J.L. Vivian, E.N. Olson & W.H. Klein: Myogenin is required for late but not early aspects of

- myogenesis during development. *J Cell Biol* 128, 563-576 (1995)
64. Braun T & H.H. Arnold: Inactivation of Myf-6 and Myf-5 genes in mice leads to alterations in skeletal muscle development. *EMBO J* 14, 1176-1186 (1995)
65. Patapoutian A, J.K. Yoon, J.H. Miner, S. Wang, K. Stark & B. Wold: Disruption of the mouse MRF4 gene identifies multiple waves of myogenesis in the myotome. *Development* 121, 3347-3358 (1995)
66. Zhang W, R.R. Behringer & E.N. Olson: Inactivation of the myogenic bHLH gene MRF4 results in up-regulation of myogenin and rib abnormalities. *Genes Dev* 9, 1388-1399 (1995)
67. Olson E, H.H. Arnold, P.W.J. Rigby & B.J. Wold: Know your neighbors: three phenotypes in null mutants of the myogenic bHLH gene MRF4. *Cell* 85, 1-4 (1996)
68. Yoon J, E.N. Olson, H.H. Arnold & B.J. Wold: Different MRF4 knockout alleles differentially disrupt Myf-5 expression: cis-regulatory interactions at the MRF4/Myf-5 locus. *Dev Biol* 188, 349-362 (1997)
69. Rawls A, J.H. Morris, M. Rudnicki, T. Braun, H.H. Arnold, W.H. Klein & E.N. Olson: Myogenin's functions do not overlap with those of MyoD or Myf-5 during mouse embryogenesis. *Dev Biol* 172, 37-50 (1995) [published erratum appear *Dev Biol* 174, 453 (1996)]
70. Rudnicki M & R. Jaenisch: The MyoD family of transcription factors and skeletal myogenesis. *BioEssays* 17, 203-209 (1995)
71. Megeney L & M.A. Rudnicki: Determination versus differentiation and the MyoD family of transcription factors. *Biochem Cell Biol* 73, 723-732 (1995)
72. Rawls A, M.R. Valdez, W. Zheng, J. Richardson, W.H. Klein & E.N. Olson: Overlapping functions of the myogenic bHLH genes MRF4 and MyoD revealed in double mutant mice. *Development* 125, 2349-2358 (1998)
73. Valdez M, J.A. Richardson, W.H. Klein & E.N. Olson: Failure of Myf-5 to support myogenic differentiation without myogenin, MyoD, and MRF4. *Dev Biol* 219, 287-298 (2000)
74. Wang Y, P.N.J. Schnegelsberg, J. Dausman & R. Jaenisch: Functional redundancy of the muscle-specific transcription factors Myf5 and myogenin. *Nature* 379, 823-825 (1996)
75. Wang Y & R. Jaenisch: Myogenin can substitute for Myf5 in promoting myogenesis but less efficiently. *Development* 124, 2507-2513 (1997)
76. Asakura A, G.E. Lyons & S.J. Tapscott: The regulation of MyoD gene expression: conserved elements mediate expression in embryonic axial muscle. *Dev Biol* 171, 386-398 (1995)
77. Goldhamer D, B.P. Brunk, A. Faerman, A. King, M. Shani & C.P. Emerson: Embryonic activation of the MyoD gene is regulated by a highly conserved distal control element. *Development* 121, 637-649 (1995)
78. Kablar B, K. Krastel, C. Ying, A. Asakura, S.J. Tapscott & M.A. Rudnicki: MyoD and Myf-5 differentially regulate the development of limb versus trunk skeletal muscle. *Development* 124, 4729-4738 (1997)
79. Kablar B, A. Asakura, K. Krastel, C. Ying, L.L. May, D.J. Goldhamer & M.A. Rudnicki: MyoD and Myf-5 define the specification of musculature of distinct embryonic origin. *Biochem Cell Biol* 76, 1079-1091 (1998)
80. Braun T, E. Bober, M.A. Rudnicki, R. Jaenisch & H.H. Arnold: MyoD expression marks the onset of skeletal myogenesis in Myf-5 mutant mice. *Development* 120, 3083-3092 (1994)
81. Kablar B & M.A. Rudnicki: Skeletal muscle development in the mouse embryo. *Histol Histopathol* 15, 649-656 (2000)
82. Kablar B, K. Krastel, C. Ying, S.J. Tapscott, D.J. Goldhamer & M.A. Rudnicki: Myogenic determination occurs independently in somites and limb buds. *Dev Biol* 206, 219-231 (1999)
83. Tajbakhsh S, D. Racancourt & M. Buckingham: Muscle progenitor cells failing to respond to positional cues adopt non-myogenic fates in myf5 null mice. *Nature* 384, 266-270 (1996)
84. Kablar B, S. Tajbakhsh & M.A. Rudnicki: Transdifferentiation of esophageal smooth to skeletal muscle is myogenic bHLH factor-dependent. *Development* 127, 1627-1639 (2000)
85. Borycki A & C.P. Emerson: Multiple tissue interactions and signal transduction pathways control somite myogenesis. *Curr Topics Dev Biol* 48, 165-224 (2000)
86. Teillet M & N. LeDouarin: Consequences of neural tube and notochord excision on the development of peripheral nervous system in the chick embryo. *Dev Biol* 98, 192-211 (1983)
87. Rong P, Teillet, M.A., C. Ziller & N. LeDouarin: The neural tube/notochord complex is necessary for vertebral but not limb and body wall striated muscle differentiation. *Development* 115, 657-672 (1992)
88. Pourquie O, M. Cotley, M.A. Teillet, C. Ordahl & N.M. LeDouarin: Control of dorsoventral patterning of somitic derivatives by notochord and floor plate. *Proc Natl Acad Sci USA* 90, 5242-5246 (1993)
89. Buffinger N & F.E. Stockdale: Myogenic specification in somites: induction by axial structures. *Development* 120, 1443-1452 (1994)
90. Spence M, J. Yip & C.A. Erickson: The dorsal neural tube organizes the dermomyotome and induces axial myocytes in the avian embryo. *Development* 122, 231-241 (1996)
91. Pownall M, K.E. Strunk & C.P. Emerson: Notochord signals control the transcriptional cascade of myogenic bHLH genes in somites of quail embryos. *Development* 122, 1475-1488 (1996)
92. Pourquie O, M. Cotley, C. Breant, & N.M. Le Douarin: Control of somite patterning by signals from the lateral plate. *Proc Natl Acad Sci USA* 92, 3219-3223 (1995)
93. Pourquie O, C.M. Fan, M. Cotley, E. Hirsinger, Y. Watanabe, C. Breant, P. Francis-West, P. Brickell, M. Tessier-Lavigne & N.M. Le Douarin: Lateral and axial signals involved in avian somite patterning: a role for BMP4. *Cell* 84, 461-471 (1996)
94. Cossu G, R. Kelly, S. Tajbakhsh, S. DiDonna, E. Vivarelli & M. Buckingham: Activation of different myogenic pathways: myf-5 is induced by the neural tube and MyoD by the dorsal ectoderm in mouse paraxial mesoderm. *Development* 122, 429-437 (1996)
95. Kenny-Mobbs T & P. Thorogood: Autonomy of differentiation in avian branchial somites and the influence of adjacent tissues. *Development* 100, 449-462 (1987)
96. Fan C & M. Tessier-Lavigne: Patterning of mammalian somites by surface ectoderm and notochord: evidence for

- sclerotomal induction by a hedgehog homologue. *Cell* 79, 1175-1186 (1994)
97. Dietrich S, F.R. Schubert & A. Lumsden: Control of dorsoventral pattern in the chick paraxial mesoderm. *Development* 124, 3895-3908 (1997)
 98. Johnson R, E. Laufer, R.D. Riddle & C. Tabin: Ectopic expression of sonic hedgehog alters dorsal-ventral patterning of somites. *Cell* 79, 1165-1173 (1994)
 99. Munsterberg A, J. Kitajewski, D.A. Bumcrot, A.P. McMahon & A.B. Lassar: Combinatorial signaling by sonic hedgehog and Wnt family members induces myogenic bHLH gene expression in the somite. *Genes Dev* 9, 2911-2922 (1995)
 100. Teillet M, Y. Watanabe, P. Jeffs, D. Duprez, F. Lapointe & N.M. LeDouarin: Sonic hedgehog is required for survival of both myogenic and chondrogenic somitic lineages. *Development* 125, 2019-2030 (1998)
 101. Asakura A & S.J. Tapscott: Apoptosis of epaxial myotome in Danforth's short-tail (Sd) mice in somites that form following notochord degeneration. *Dev Biol* 203, 276-289 (1998)
 102. Chiang C, Y. Litingtung, E. Lee, K.E. Young, J.L. Corden, H. Westphal & P.A. Beachy: Cyclopia and defective axial patterning in mice lacking sonic hedgehog gene function. *Nature* 383, 407-413 (1996)
 103. Borycki A, B. Brunk, S. Tajbakhsh, M. Buckingham, C. Chiang & C.P. Emerson: Sonic hedgehog controls epaxial muscle determination through Myf5 activation. *Development* 126, 4053-4063 (1999)
 104. Stern H, A.M. Brown & S.D. Hauschka: Myogenesis in paraxial mesoderm: preferential induction by dorsal neural tube and by cells expressing Wnt-1. *Development* 121, 3675-3686 (1995)
 105. Marcelle C, M.R. Stark & M. Bronner-Fraser: Coordinate actions of BMPs, Wnts, Shh and Noggin mediate patterning of the dorsal somite. *Development* 124, 3955-3963 (1997)
 106. Ikeya M & S. Takada: Wnt signaling from the dorsal neural tube is required for the formation of the medial dermomyotome. *Development* 125, 4969-4976 (1998)
 107. Tajbakhsh S, U. Borello, E. Vivarelli, R. Kelly, J. Papkoff, D. Duprez, M. Buckingham & G. Cossu: Differential activation of Myf5 and MyoD by different Wnts in explants of mouse paraxial mesoderm and the later activation of myogenesis in the absence of Myf5. *Development* 125, 4155-4162 (1998)
 108. Amthor H, B. Christ, M. Weil & K. Patel: The importance of timing differentiation during limb muscle development. *Curr Biol* 8, 642-652 (1998)
 109. Hirsinger E, D. Duprez, C. Jouve, P. Malapert, J. Cooke & O. Pourquie: Noggin acts downstream of Wnt and sonic hedgehog to antagonize BMP4 in avian somite patterning. *Development* 124, 4605-4614 (1997)
 110. Reshef R, M. Maroto & A.B. Lassar: Regulation of dorsal somitic cell fates: BMPs and noggin control the timing and pattern of myogenic regulator expression. *Genes Dev* 12, 290-303 (1998)
 111. Stern H, J. Lin-Jones & S.D. Hauschka: Synergistic interactions between bFGF and TGF- β family member may mediate myogenic signals from the neural tube. *Development* 124, 3511-3523 (1997)
 112. Artavanis-Tsakonas S, M.D. Rand & R.J. Lake: Notch signaling: cell fate control and signal integration in development. *Science* 284, 770-776 (1999)
 113. Kopan R, J.S. Nye & H. Weintraub: The intracellular domain of mouse Notch: a constitutively activated repressor of myogenesis directed at the basic helix-loop-helix region of MyoD. *Development* 120, 2385-2396 (1994)
 114. Weinmaster G, V.J. Roberts & G. Lemke: Notch2: a second mammalian Notch gene. *Development* 116, 931-941 (1992)
 115. Williams R, U. Lendahl & M. Lardelli: Complementary and combinatorial patterns of Notch gene family expression during mouse development. *Mech Dev* 53, 357-368 (1995)
 116. Franz T, R. Kothary, M.A. Surani, Z. Halata & M. Grim: The splotch mutation interferes with muscle development in the limbs. *Anat Embryol* 187, 153-160 (1993)
 117. Goulding M, A. Lumsden & A.J. Paquette: Regulation of Pax-3 expression in the dermomyotome and its role in muscle development. *Development* 120, 957-971 (1994)
 118. Bober E, T. Franz, H.H. Arnold, P. Gruss & P. Tremblay: Pax-3 is required for the development of limb muscles: a possible role for the migration of dermomyotomal muscle progenitor cells. *Development* 120, 603-612 (1994)
 119. Williams B & C.P. Ordahl: Pax-3 expression in segmental mesoderm marks early stages in myogenic cell specification. *Development* 120, 785-796 (1994)
 120. Daston G, E. Lamar, M. Olivier & M. Goulding: Pax-3 is necessary for migration but not differentiation of limb muscle precursors in the mouse. *Development* 122, 1017-1027 (1996)
 121. Amthor H, B. Christ & K. Patel: A molecular mechanism enabling continuous embryonic muscle growth: a balance between proliferation and differentiation. *Development* 126, 1041-1053 (1999)
 122. Maroto M, R. Reshef, A.E. Munsterberg, S. Koester, M. Goulding & A.B. Lassar: Ectopic Pax-3 activates MyoD and Myf-5 expression in embryonic mesoderm and neural tissue. *Cell* 89, 139-148 (1997)
 123. Tajbakhsh S, D. R. Rocancourt, G. Cossu & M. Buckingham: Redefining the genetic hierarchies controlling skeletal myogenesis: Pax-3 and Myf-5 act upstream of MyoD. *Cell* 89, 127-138 (1997)
 124. Bladt F, D. Riethmacher, S. Isenmann, A. Aguzzi & C. Birchmeier: Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud. *Nature* 376, 768-771 (1995)
 125. Maina F, F. Casagrande, E. Audero, A. Simeone, P.M. Comoglio, F. Klein & C. Ponzetto: Uncoupling of Grb2 from the Met receptor in vivo reveals complex roles in muscle development. *Cell* 87, 531-542 (1996)
 126. Dietrich S, F. Abou-Rebyeh, H. Brohmann, F. Bladt, E. Sonnenber-Riethmacher, T. Yamaai, A. Lumsden, B. Brand-Saberi & C. Birchmeier: The role of SF/HGF and c-Met in the development of skeletal muscle. *Development* 126, 1621-1629 (1999)
 127. Schafer K & T. Braun: Early specification of limb muscle precursor cells by the homeobox gene *lhx1*. *Nat Genet* 23, 213-216 (1999)
 128. Brohmann H, K. Jagla & C. Birchmeier: The role of *lhx1* in migration of muscle progenitor cells. *Development* 127, 437-445 (2000)

129. Gross M, L. Moran-Rivard, T. Velasquez, M.N. Nakatsu, K. Jagla & M. Goulding: Lbx1 is required for muscle precursor migration along a lateral pathway into the limb. *Development* 127, 413-424 (2000)
130. Mennerich D, K. Schafer & T. Braun: Pax-3 is necessary but not sufficient for lbx1 expression in myogenic precursor cells of the limb. *Mech Dev* 73, 147-158 (1998)
131. Woloshin P, K. Song, C. Degen, A.M. Killary, D.J. Goldhamer, D. Sassoon & M.J. Thayer: MSX1 inhibits MyoD expression in fibroblast x 10T1/2 cell hybrids. *Cell* 82, 611-620 (1995)
132. Bendall A, J. Ding, G. Hu, M.M. Shen & C. Abate-Shen: Msx1 antagonizes the myogenic activity of Pax3 in migrating limb muscle precursors. *Development* 126, 4965-4976 (1999)
133. Houzelstein D, G. Auda-Boucher, Y. Cheraud, T. Rouaud, I. Blanc, S. Tajbakhsh, M.E. Buckingham, J. Fontaine-Perus & B. Robert: The homeobox gene Msx1 is expressed in a subset of somites, and in muscle progenitor cells migrating into the forelimb. *Development* 126, 2689-2701 (1999)
134. Heanue T, R. Reshef, R.J. Davis, G. Mardon, G. Oliver, S. Tomarev, A.B. Lassar & C.J. Tabin: Synergistic regulation of vertebrate muscle development by Dach2, Eya2, and Six1, homologs of genes required for Drosophila eye formation. *Genes Dev* 13, 3231-3243 (1999)
135. Relaix F & M. Buckingham: From insect eye to vertebrate muscle: redeployment of a regulatory network. *Genes Dev* 13, 3171-3178 (1999)
136. Andres V & K. Walsh: Myogenin expression, cell cycle withdrawal, and phenotypic differentiation are temporally separable events that precede cell fusion upon myogenesis. *J Cell Biol* 132, 657-666 (1996)
137. Walsh K & H. Perlman: Cell cycle exit upon myogenic differentiation. *Curr Opin Genet Dev* 7, 597-602 (1997)
138. Lipinski M & T. Jacks: The retinoblastoma gene family in differentiation and development. *Oncogene* 18, 7873-7882 (1999)
139. Tiainen M, D. Spitkovsky, P. Jansen-Durr, A. Sacchi & M. Crescenzi: Expression of E1A in terminally differentiated muscle cells reactivates the cell cycle and suppresses tissue-specific genes by separable mechanisms. *Mol Cell Biol* 16, 5302-5312 (1996)
140. Mal A, D. Chattopadhyay, M.K. Ghosh, R.Y. Poon, T. Hunter & M.L. Harter: p21 and retinoblastoma protein control the absence of DNA replication in terminally differentiated muscle cells. *J Cell Biol* 149, 281-292 (2000)
141. Schneider J, W. Gu, L. Zhu, V. Mahdavi & B. Nadal-Ginard: Reversal of terminal differentiation mediated by p107 in Rb^{-/-} muscle cells. *Science* 264, 1467-1471 (1994)
142. Novitch B, G.L. Mulligan, T. Jacks & A.B. Lassar: Skeletal muscle cells lacking the retinoblastoma protein display defects in muscle gene expression and accumulate in S and G2 phases of the cell cycle. *J Cell Biol* 135, 441-456 (1996)
143. Gu W, J.W. Schneider, G. Condorelli, S. Kaushal, V. Mahdavi & B. Nadal-Ginard: Interaction of myogenic factors and the retinoblastoma protein mediates muscle cell commitment and differentiation. *Cell* 72, 309-324 (1993)
144. Novitch B, D.B. Spicer, P.S. Kim, W.L. Cheung & A.B. Lassar: pRb is required for MEF2-dependent gene expression as well as cell-cycle arrest during skeletal muscle differentiation. *Curr Biol* 9, 449-459 (1999)
145. Rao S, C. Chu & D.S. Kohtz: Ectopic expression of cyclin D1 prevents activation of gene transcription by myogenic basic helix-loop-helix regulators. *Mol Cell Biol* 14, 5259-5267 (1994)
146. Skapek S, J. Rhee, D.B. Spicer & A.B. Lassar: Inhibition of myogenic differentiation in proliferating myoblasts by cyclin D1-dependent kinases. *Science* 267, 1022-1024 (1995)
147. Skapek S, J. Rhee, P.S. Kim, B.G. Novitch & A.B. Lassar: Cyclin-mediated inhibition of muscle gene expression via a mechanism that is independent of pRB hyperphosphorylation. *Mol Cell Biol* 16, 7043-7053 (1996)
148. Song A, Q. Wang, M.G. Goebel & M.A. Harrington: Phosphorylation of nuclear MyoD is required for its rapid degradation. *Mol Cell Biol* 18, 4994-4999 (1998)
149. Kitzmann M, G. Carnac, M. Vandromme, M. Primig, H.J.C. Lamb & A. Fernandez: The muscle regulatory factors MyoD and Myf-5 undergo distinct cell cycle-specific expression in muscle cells. *J Cell Biol* 142, 1447-1459 (1998)
150. Guttridge D, C. Albanese, J.Y. Reuther, R.G. Pestell & A.S. Baldwin: NF- κ B controls cell growth and differentiation through transcriptional regulation of cyclin D1. *Mol Cell Biol* 19, 5785-5799 (1999)
151. Halevy O, B.G. Novitch, D.B. Spicer, S.X. Skapek, J. Rhee, G.J. Hannon, D. Beach & A.B. Lassar: Correlation of terminal cell cycle arrest of skeletal muscle with induction of p21 by MyoD. *Science* 267, 1018-1021 (1995)
152. Wang J & K. Walsh: Resistance to apoptosis conferred by Cdk inhibitors during myocyte differentiation. *Science* 273, 359-361 (1996)
153. Reynaud E, K. Pospel, M. Guiller, M.P. Leibovitch & S.A. Leibovitch: p57KIP2 stabilizes the MyoD protein by inhibiting cyclin E-Cdk2 kinase activity in growing myoblasts. *Mol Cell Biol* 19, 7621-7629 (1999)
154. Zhang P, C. Wong, D. Liu, M. Finegold, J.W. Harper & S.J. Elledge: p21CIP1 and p57KIP2 control muscle differentiation at the myogenin step. *Genes Dev* 13, 213-224 (1999)
155. Zhang J, Q. Wei, X. Zhao & B.M. Paterson: Coupling of the cell cycle and myogenesis through the cyclin D1-dependent interaction of MyoD with cdk4. *EMBO J* 18, 926-933 (1999)
156. Zhang J, X. Zhao, Q. Wei & B.M. Paterson: Direct inhibition of G(1) cdk kinase activity by MyoD promotes myoblast cell cycle withdrawal and terminal differentiation. *EMBO J* 18, 6983-6993 (1999)
157. Reynaud E, M.P. Leibovitch, L.A. Tintignac, K. Pospel, M. Guiller & S.A. Leibovitch: Stabilization of MyoD by direct binding to p57Kip2. *J Biol Chem* 275, 18767-18776 (2000)
158. Black B & E.N. Olson: Transcriptional control of muscle development by myocyte enhancer factor-2 (MEF2) proteins. *Annu Rev Cell Dev Biol* 14, 167-196 (1998)
159. Naya F & E.N. Olson: Mef2: a transcriptional target for signaling pathways controlling skeletal muscle growth and differentiation. *Curr Opin Cell Biol* 11, 683-688 (1999)

160. Edmondson D, T.C. Cheng, P. Cserjesi, T. Chakraborty & E.N. Olson: Analysis of the myogenin promoter reveals an indirect pathway for positive autoregulation mediated by the muscle-specific enhancer factor Mef-2. *Mol Cell Biol* 12, 3665-3677 (1994)
161. Naidu P, D.C. Ludolph, R.Q. To, T.J. Hinterberger & S.F. Konieczny: Myogenin and Mef2 function synergistically to activate the *mrf4* promoter during myogenesis. *Mol Cell Biol* 15, 2707-2718 (1995)
162. Molkentin J, B.L. Black, J.F. Martin & E.N. Olson: Cooperative activation of muscle gene expression by MEF2 and myogenic bHLH proteins. *Cell* 83, 1125-1136 (1995)
163. Black B, J.D. Molkentin & E.N. Olson: Multiple roles for the MyoD basic region in transmission of transcriptional activation signals and interaction with MEF2. *Mol Cell Biol* 18, 69-77 (1998)
164. Lily B, B. Zhao, G. Ranganayakulu, B.M. Paterson, R.A. Schultz & E.N. Olson: Requirement of MADS domain transcription factor D-MEF2 for muscle formation in *Drosophila*. *Science* 267, 688-693, (1995)
165. Lin Q, J. Schwarz, C. Bucana & E.N. Olson: Control of mouse cardiac morphogenesis and myogenesis by transcription factor Mef2c. *Science* 276, 1404-1407 (1997)
166. Naya F, C. Wu, J.A. Richardson, P. Overbeek & E.N. Olson: Transcriptional activity of MEF2 during mouse embryogenesis monitored with a MEF2-dependent transgene. *Development* 126, 2045-2052 (1999)
167. Hunter T.: Signaling-2000 and beyond. *Cell* 100, 113-127 (2000)
168. Li L, J. Zhou, G. James, R. Heller-Harrison, M.P. Czech & E.N. Olson: FGF inactivates myogenic helix-loop-helix proteins through phosphorylation of a conserved protein kinase C site in their DNA-binding domains. *Cell* 71, 1181-1194 (1992)
169. Hardy S, Y. Kong & S.F. Konieczny: Fibroblast growth factor inhibits MRF4 activity independently of the phosphorylation status of a conserved threonine residue within the DNA-binding domain. *Mol Cell Biol* 13, 5943-5956 (1993)
170. Kong Y, S.E. Johnson, E.J. Taparowsky & S.J. Konieczny: Ras p21val inhibits myogenesis without altering the DNA binding or transcriptional activities of the myogenic basic helix-loop-helix factors. *Mol Cell Biol* 15, 5205-5213 (1995)
171. Ramrocki M, S.E. Johnson, M.A. White, C.L. Ashendel, S.F. Konieczny & E.J. Taparowsky: Signaling through mitogen-activated protein kinase and Rac/Rho does not duplicate the effects of activated Ras on skeletal myogenesis. *Mol Cell Biol* 17, 3547-3555 (1997)
172. Weyman C & A. Wolfman: Mitogen-activated protein kinase kinase (MEK) activity is required for inhibition of skeletal muscle differentiation by insulin-like growth factor 1 or fibroblast growth factor 2. *Endocrinology* 139, 1794-1800 (1998)
173. Bennett A & M.K. Tonks: Regulation of distinct stages of skeletal muscle differentiation by mitogen-activated protein kinases. *Science* 278, 1288-1291 (1997)
174. Kaliman P, F. Vinals, X. Testar, M. Palacin & A. Zorzano: Phosphatidylinositol 3-kinase inhibitors block differentiation of skeletal muscle cells. *J Biol Chem* 271, 19146-19151 (1996)
175. Coolican S, D.S. Samuel, D.Z. Ewton, F.J. McWade & J.R. Florini: The mitogenic and myogenic actions of insulin-like growth factors utilize distinct signaling pathways. *J Biol Chem* 272, 6653-6662 (1997)
176. Jiang B, J.Z. Zheng & P.K. Vogt: An essential role of phosphatidylinositol 3-kinase in myogenic differentiation. *Proc Natl Acad Sci USA* 95, 14179-14183 (1998)
177. Fujio Y, K. Guo, T. Mano, Y. Mitsuuchi, J.R. Testa & K. Walsh: Cell cycle withdrawal promotes myogenic induction of Akt, a positive modulator of myocyte survival. *Mol Cell Biol* 19, 5073-5082 (1999)
178. Jiang B, M. Aoki, J.Z. Zheng, J. Li & P.K. Vogt: Myogenic signaling of phosphatidylinositol 3-kinase requires the serine-threonine kinase Akt/protein kinase B. *Proc Natl Acad Sci USA* 96, 2077-2081 (1999)
179. Zimmermann S & K. Moelling: Phosphorylation and regulation of Raf by Akt (protein kinase B). *Science* 286, 1741-1745 (1999)
180. Rommel C, B.A. Clark, S. Zimmermann, L. Nunez, R. Rossman, K. Reid, K. Moelling, G.D. Yancopoulos & D.J. Glass: Differentiation stage-specific inhibition of the Raf-MEK-ERK pathway by Akt. *Science* 286, 1738-1741 (1999)
181. Lawlor M, X. Feng, D.R. Everding, K. Sieger, C.E.H. Stewart & P. Rotwein: Dual control of muscle cell survival by distinct growth factor-regulated signaling pathways. *Mol Cell Biol* 20, 3256-3265 (2000)
182. Marshall C.: Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-related kinase activation. *Cell* 80, 179-185 (1995)
183. Han J, Y. Jiang, V.V. Kravchenko & R.J. Ulevitch: Activation of the transcription factor MEF2C by the MAP kinase p38 in inflammation. *Nature* 386, 296-299 (1997)
184. Kato Y, V.V. Kravchenko, R.I. Tapping, J. Han, R.J. Ulevitch & J.D. Lee: BMK1/ERK5 regulates serum-induced early gene expression through transcription factor MEF2C. *EMBO J* 16, 7054-7066 (1997)
185. Yang S, A. Galanis & A.D. Sharrocks: Targeting of p38 mitogen-activated protein kinases to MEF2 transcription factors. *Mol Cell Biol* 19, 4028-4038 (1999)
186. Zhao M, L. New, V.V. Kravchenko, Y. Kato, H. Gram, F. diPadova, E.N. Olson, R.J. Ulevitch & J. Han: Regulation of the MEF2 family of transcription factors by p38. *Mol Cell Biol* 19, 21-30 (1999)
187. Lechner C, M.A. Zahalka, J.F. Giot, N.P.H. Moller & A. Ullrich: ERK6, a mitogen-activated protein kinase involved in C2C12 myoblast differentiation. *Proc Natl Acad Sci USA* 93, 4355-4359 (1996)
188. Zetser A, E. Gredinger & E. Bengal: p38 mitogen-activated protein kinase pathway promotes skeletal muscle differentiation. *J Biol Chem* 274, 5193-5200 (1999)
189. Wang X, K. Diener, C.L. Manthey, S.-w. Wang, B. Rosenzweig, J. Bray, J. Delaney, C.N. Cole, P.Y. Chan-Hui, N. Mantlo, H.S. Lichenstein, M. Zukowski & Z. Yao: Molecular cloning and characterization of a novel p38 mitogen-activated protein kinase. *J Biol Chem* 272, 23668-23674 (1997)
190. Crabtree G.: Generic signals and specific outcomes: signaling through Ca^{2+} , calcineurin, and NF-AT. *Cell* 96, 611-614 (1999)
191. Chin E, E.N. Olson, J.A. Richardson, Q. Yang, C. Humphries, J.M. Shelton, H. Wu, W. Zhu, R. Bassel-Duby & R.S. Williams: A calcineurin-dependent transcriptional pathway controls skeletal muscle fiber type. *Genes Dev* 12, 2499-2509 (1998)

192. Dunn S, J.L. Burns & R.N. Michel: Calcineurin is required for skeletal muscle hypertrophy. *J Biol Chem* 274, 21908-21912 (1999)
193. Naya F, B. Mercer, J. Shelton, J.A. Richardson, R.S. Williams & E.N. Olson: Stimulation of slow skeletal muscle fiber gene expression by calcineurin in vivo. *J Biol Chem* 275, 4545-4548 (2000)
194. Youn H, L. Sun, R. Prywes & J.O. Liu: Apoptosis of T cells mediated by Ca²⁺-induced release of the transcription factor MEF2. *Science* 286, 790-793 (1999)
195. Mao Z, A. Bonni, F. Xia, M. Nadal-Vicens & M.E. Greenberg: Neuronal activity-dependent cell survival mediated by transcription factor MEF2. *Science* 286, 785-790 (1999)
196. Blaaser F, N. Ho, R. Prywes & T.A. Chatila: Ca²⁺-dependent gene expression mediated by MEF2 transcription factors. *J Biol Chem* 275, 197-209 (2000)
197. Trouche D, M. Grigoriev, J. Lenormand, P. Robin, S.A. Leibovitch, P. Sassone-Corsi & A. Harel-Bellan: Repression of the c-fos promoter by MyoD on muscle cell differentiation. *Nature* 363, 79-82 (1993)
198. Groisman R, H. Masutani, M.-P. Leibovitch, P. Robin, I. Soudant, D. Trouche & A. Harel-Bellan: Physical interaction between the mitogen-responsive serum response factor and myogenic basic-helix-loop-helix proteins. *J Biol Chem* 271, 5258-5264 (1996)
199. Bengal E, L. Ransone, R. Scharfmann, V.J. Dwarki, S.J. Tapscot, H. Weintraub & I.M. Verma: Functional antagonism between c-Jun and MyoD proteins: a direct physical association. *Cell* 68, 507-519 (1992)
200. Li L, J.C. Chambard, M. Karin & E.N. Olson: Fos and Jun repress transcriptional activation by myogenin and MyoD: the amino terminus of Jun can mediate repression. *Genes Dev* 6, 676-689 (1992)
201. Langlands K, X., Yin, G. Anand & E.V. Prochownik: Differential interactions of Id proteins with basic-helix-loop-helix transcription factors. *J Biol Chem* 272, 19785-19793 (1997)
202. Neuhold L & B. Wold: HLH forced dimers: tethering MyoD and E47 generates a dominant positive myogenic factor insulated from negative regulation by Id. *Cell* 74, 1033-1042 (1993)
203. Lu J, R. Webb, J.A. Richardson & E.N. Olson: MyoR: a muscle-restricted basic helix-loop-helix transcription factor that antagonizes the actions of MyoD. *Proc Natl Acad Sci USA* 96, 552-557 (1999)
204. Leibovitch M, B. Solhonne, M. Guillier, P. Verelle & S.A. Leibovitch: Direct relationship between the expression of tumor suppressor H19 mRNA and c-mos proto-oncogene during myogenesis. *Oncogene* 10, 251-260 (1995)
205. Lenormand J, B. Benayoun, M. Guillier, M. Vandromme, M.P. Leibovitch & S.A. Leibovitch: Mos activates myogenic differentiation by promoting heterodimerization of MyoD and E12 proteins. *Mol Cell Biol* 17, 584-593 (1997)
206. Solhonne B, J.L. Lenormand, K. Pelpel, M.P. Leibovitch & S.A. Leibovitch: MyoD binds to Mos and inhibits the Mos/MAP kinase pathway. *FEBS Lett* 461, 107-110 (1999)
207. Kong Y, M.J. Flick, A.J. Kudla & S.F. Konieczny: Muscle LIM protein promotes myogenesis by enhancing the activity of MyoD. *Mol Cell Biol* 17, 4750-4760 (1999)
208. Giles R, D.J.M. Peters & M.H. Breuning: Conjunction dysfunction: CBP/p300 in human disease. *Trends Genet* 14, 178-183 (1998)
209. Puri P, M.L. Avantiaggiati, C. Balsano, N. Sang, A. Graessmann, A. Giorano & M. Levvero: p300 is required for MyoD-dependent cell cycle arrest and muscle-specific gene expression. *EMBO J* 16, 369-383 (1997)
210. Sartorelli V, J. Huang, Y. Hamamori & L. Kedes: Molecular mechanisms of myogenic coactivation by p300: direct interaction with the activation domain of MyoD and with the MADS box of MEF2C. *Mol Cell Biol* 17, 1010-1026 (1997)
211. Puri P, V. Sartorelli, X.J. Yang, Y. Hamamori, V.V. Ogryzko, B.H. Howard, L. Kedes, J.Y. Wang, A. Graessmann, Y. Nakatani & M. Levvero: Differential roles of p300 and PCAF acetyltransferases in muscle differentiation. *Mol Cell* 1, 35-45 (1997)
212. Sartorelli V, P.L. Puri, Y. Hamamori, V. Ogryzko, G. Chung, Y. Nakatani, J.Y.J. Wang & L. Kedes: Acetylation of MyoD directed by PCAF is necessary for the execution of the muscle program. *Mol Cell* 4, 725-734 (1999)
213. Bailey P, M. Downes, P. Lau, J. Harris, S.L. Chen, Y. Hamamori, V. Sartorelli & G.E. Muscat: The nuclear hormone receptor corepressor N-CoR regulates differentiation: N-CoR directly interacts with MyoD. *Mol Endocrinol* 13, 1155-1168 (1999)
214. Bischoff R.: The satellite cell and muscle regeneration. In: Myology. Eds: Engel A, Franzini-Armstrong C, McGraw-Hill, NY. 1, 97-118 (1994)
215. Grounds M.: Age-associated changes in the response of skeletal muscle cells to exercise and regeneration. *Ann N Y Acad Sci* 854, 78-91 (1998)
216. Seale P & M.A. Rudnicki: A new look at the origin, function, and "stem-cell" status of muscle satellite cells. *Dev Biol* 106, 115-124 (2000)
217. Cornelison D & B.J. Wold: Single-cell analysis of regulatory gene expression in quiescent and activated mouse skeletal muscle satellite cells. *Dev Biol* 191, 270-283 (1997)
218. Megeney L, B. Kablar, K. Garrett, J.E. Anderson & M.A. Rudnicki: MyoD is required for myogenic stem cell function in adult skeletal muscle. *Genes Dev* 10, 1173-1183 (1996)
219. Sabourin L, A. Girgis-Gabardo, P. Seale, A. Asakura & M.A. Rudnicki: Reduced differentiation potential of primary MyoD^{-/-} myogenic cells derived from adult skeletal muscle. *J Cell Biol* 144, 631-643 (1999)
220. Yablonka-Reuveni Z, M.A. Rudnicki, A.J. Rivera, M. Primig, J.E. Anderson & P. Natanson: The transition from proliferation to differentiation is delayed in satellite cells from mice lacking MyoD. *Dev Biol* 210, 440-455 (1999)
221. Sabourin L & M.A. Rudnicki: The molecular regulation of myogenesis. *Clin Genet* 57, 16-25 (2000)
222. Garry D, Q. Yang, R. Bassel-Duby, R.S. Williams: Persistent expression of MNF identifies myogenic stem cells in postnatal muscles. *Dev Biol* 188, 280-294 (1997)
223. Yang Q, R. Bassel-Duby, R.S. Williams: Transient expression of a winged-helix protein, MNF-beta, during myogenesis. *Mol Cell Biol* 17, 5236-5243 (1997)
224. Garry D, A. Meeson, J. Elterman, Y. Zhao, P. Yang, R. Bassel-Duby, R.S. Williams: Myogenic stem cell function is impaired in mice lacking the forkhead/winged helix protein MNF. *Proc Natl Acad Sci USA* 97, 5416-5421 (2000)
225. deLapeyriere O, V. Ollendorff, J. Planche, M.O. Ott, S. Pizette, F. Coulier & D. Birnbaum: Expression of the Fgf6 gene is restricted to developing skeletal muscle in the mouse embryo. *Development* 118, 601-611 (1993)

226. Coulier F, S. Pizette, V. Ollendorf, O. deLapeyriere & D. Birnbaum: The human and mouse fibroblast growth factor 6 (FGF6) genes and their products: possible implication in muscle development. *Prog Growth Factor Res* 5, 1-14 (1994)
227. Pizette S, F. Coulier, D. Birnbaum & O. deLapeyriere: FGF6 modulates the expression of fibroblast growth factor receptors and myogenic genes in muscle cells. *Exp Cell Res* 224, 143-151 (1996)
228. Floss T, H.H. Arnold & T. Braun: A role for FGF-6 in skeletal muscle regeneration. *Genes Dev* 11, 2040-2051 (1997)
229. Fiore F, J. Planche, P. Gibier, A. Sebillé, O. deLapeyriere & D. Birnbaum: Apparent normal phenotype of Fgf6^{-/-} mice. *Int J Dev Biol* 41, 639-642 (1997)
230. McPherron A, A.M. Lawler & S.J. Lee: Regulation of skeletal muscle mass in mice by a new TGF- β superfamily member. *Nature* 387, 83-90 (1997)
231. Luo K, S.L. Stroschein, W. Wang, D. Chen, E. Martens, S. Zhou & Q. Zhou: The ski oncoprotein interacts with the Smad proteins to repress TGF β signaling. *Genes Dev* 13, 2196-2206 (1999)
232. Stroschein S, W. Wang, S. Zhou, Q. Zhou & K. Luo: Negative feedback regulation of TGF- β signaling by the SnoN oncoprotein. *Science* 286, 771-774 (1999)
233. Colmenares C & E. Stavnezer: The ski oncogene induces muscle differentiation in quail embryo cells. *Cell* 59, 293-303 (1989)
234. Berk M, S.Y. Desai, H.C. Heyman & C. Colmenares: Mice lacking the ski proto-oncogene have defects in neurulation, craniofacial patterning, and skeletal muscle development. *Genes Dev* 11, 2029-2039 (1997)
235. Cossu G, P. Cicinelli, C. Fieri, M. Coletta & M. Molinaro: Emergence of TPA-resistant 'satellite' cells during muscle histogenesis of human limb. *Exp Cell Res* 160, 403-411 (1985)
236. De Angelis L, L. Berghella, M. Coletta, L. Lattanzi, M. Zanchi, M.G. Cusella-De Angelis, C. Ponzetto & G. Cossu: Skeletal myogenic progenitors originating from embryonic dorsal aorta coexpress endothelial and myogenic markers and contribute to postnatal muscle growth and regeneration. *J Cell Biol* 147, 869-877 (1999)
237. Ferrari G, G. Cusella-De Angelis, M. Coletta, E. Paolucci, A. Stornaiuolo, G. Cossu & F. Mavilio: Muscle regeneration by bone-marrow-derived myogenic progenitors. *Science* 279, 1528-1530 (1999)
238. Bittner R, C. Schofer, K. Weipoltshammer, S. Ivanova, B. Streubel, E. Hauser, M. Freilinger, H. Hoyer, A. Elbe-Burger & F. Wachtler: Recruitment of bone-marrow-derived cells by skeletal and cardiac muscle in adult dystrophic mdx mice. *Anat Embryol* 199, 391-396 (1999)
239. Gussoni E, Y. Soneoka, C.D. Strickland, E.A. Buzney, M.K. Khan, A.F. Flint, L.M. Kunkel & R.C. Mulligan: Dystrophin expression in the mdx mouse restored by stem cell transplantation. *Nature* 401, 390-394 (1999)
240. Goodell M, K. Brose, G. Paradis, A.S. Conner & R.C. Mulligan: Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. *J Exp Med* 183, 1797-1806 (1996)
241. Goodell M, M. Rosenzweig, H. Kim, D.F. Marks, M. DeMaria, G. Paradis, S.A. Grupp, C.A. Sieff, R.C.

- Mulligan: Dye efflux studies suggest that hematopoietic stem cells expressing low or undetectable levels of CD34 antigen exist in multiple species. *Nat Med* 3, 1337-1345 (1997)
242. Jackson K, T. Mi & M.A. Goodell: Hematopoietic potential of stem cells isolated from murine skeletal muscle. *Proc Natl Acad Sci USA* 96, 14482-14486 (1999)
243. Bjornson C, R.L. Rietze, B.A. Reynolds, M.C. Magli & A.L. Vescovi: Turning brain into blood: a hematopoietic fate adopted by adult neural stem cells in vivo. *Science* 283, 534-537 (1999)
244. Weissman I: Stem cells: units of development, units of regeneration, and units of evolution. *Cell* 100, 157-168 (2000)

Key Words: Myogenesis, myogenic regulatory factors, gene targeting, development, myoblast, cell migration, satellite cell, stem cell, signal transduction, skeletal muscle, Review

Send correspondence to: Dr Michael A. Rudnicki, Ottawa Hospital Research Institute, 501 Smyth Road, Ottawa, Ontario, Canada K1H 8L6, Tel: 613-739-6740, Fax: 613-7378803, E-mail: mrudnicki@ottawahospital.on.ca

This manuscript is available on line at:

<http://www.bioscience.org/2000/v5/d/perry/fulltext.htm>